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ABSTRACT
Breaking the Organic Mold: Introducing Copper into the
Influenza A M2 Arena with Neutral and
Divalent Complexes
Jonathan D. Lynch
Department of Chemistry and Biochemistry, BYU
Master of Science
Influenza A (IVA) continues to pose a growing global threat even as current medications are
becoming less effective. One of the main avenues of research into new anti-IVA drugs is its
homotetrameric Matrix 2 proton channel (M2A), without which the virus would be unable to
release its viral RNA into the host cell. The drug amantadine used to bind and block M2A until
near-ubiquitous resistance formed as an M2A-S31N mutation, starting around 1995 and
proceeding to 2005 when amantadine was disallowed for use as an anti-IVA drug. The standard
organic structure currently being used for M2A inhibitor research comprises an adamantyl foot
group, a heterocyclic aryl body group, and a cyclic head group. A sample set of compounds with
this standard structure was compared and reviewed, focusing on positive and negative moieties
and modifications. Modifications on the foot group were all more or less detrimental, body
groups with two heteroatoms were advantageous, and larger head groups appeared better. Four
other scaffolds known to literature were proposed for further study due to beneficial aspects of
each.
Where most anti-M2A research deals exclusively with organic compounds, metals and their
potential in drugs have been almost entirely ignored due to the increased toxicity they bring. Free
copper was found in past research to be the only first-row transition metal to show significant
M2A-inhibitory activity, proposed to do so by binding the H37 cluster that acts as a pHdependent control switch for the channel. Six overall-neutral copper complexes were synthesized
as a combination of amantadine, cyclooctylamine, and null scaffolds with two of either acetate or
acetamide arms as chelators. The complexes were found to block both M2A-WT and M2AS31N. Along with CuCl2, though, they had little to no effect on M2A-H37A, providing
confirming evidence that the copper binds at the H37 tetrad. Only one complex,
Cu(cyclooctylamineiminodiacetate), outperformed CuCl2 in channel block studies and efficacy
against two IVA strains, but all of the complexes were found to have lower cytotoxicity. Because
M2-H37 is highly conserved, these complexes show promise for further testing against all strains
of influenza A.
Five net-divalent copper complexes were then synthesized with multiple aza or amine groups
as chelators. The complexes failed to show any significant activity against M2A, however, which
was thought to be due to size or polarity rejection or electromagnetic repulsion. One of the
ligands, though, an adamantyl derivative of a tetraaza macrocycle, was a novel compound, and
its copper complex, along with two others, were unknown to the CCDC database. The three
complexes were characterized by X-ray diffraction and discussed.
Keywords: medicinal metals, tridentate or tetradentate chelation, proton transport, cyclen crystal
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CHAPTER 1

:

Optimization of Organic Influenza A M2-S31N Channel Inhibitors:
A Review of Commonalities and Differences
Abstract
Research on inhibiting influenza A Matrix 2 protein (M2A) spans a number of methods with
overlap among research groups; focus on methods that have shown positive results would help in
drug development of new M2A inhibitors. A comparison of a select sample set of compounds
from the literature is given, focusing on finding beneficial and detrimental modifications to the
standard structure currently being used for inhibitors, comprising an amantadyl foot group, a
heterocyclic aryl body group, and a cyclic head group. The unmodified amantadyl moiety was
found to be the best foot group, though alcohol addition provided mixed results. The best body
groups were found to be those with two substituted carbons in the ring, namely, for the sample
set in this study, 2-azafuran and pyrazine. The best head groups were found to be larger ring
systems, either from addition of side groups or larger ring sizes; sizes up to 8-membered rings
were compared with increasing channel block. Aromaticity of the head group seemed to make
little to no difference. Derivatives of amantadine, rimantadine, spiropiperidine, and
cyclooctylamine are also proposed as alternative foot groups with different constraints and
customizability than amantadine.
Introduction
In the western hemisphere alone, disease associated with seasonal influenza virus A (IVA)
causes approximately 85,000 human deaths annually.1 While most viruses exhibit either high
transmittance or high mortality, modern mutations in IVA have pointed inexorably toward the
evolution of a virus with both characteristics, making a disastrous pandemic in the future
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inevitable.2 Indeed, the World Health Organization has called the looming pandemic an
“evolving threat,” emphasizing that any local outbreak of such a mutant IVA strain could rapidly
become a global problem.3 In light of this threat, governments across the globe have, in recent
years, prioritized IVA research in an attempt to minimize the loss of life from the predicted
pandemic.4
Much of this anti-IVA research is geared toward developing therapeutics to treat influenza A
patients more quickly and effectively than current methods, as opposed to those that act in a
prophylactic capacity. Those treatments would be expected to help infected persons overcome
the illness faster while decreasing the mortality rate associated with influenza infections by
helping terminal infection cases end without loss of human life. Additionally, in the case of an
IVA pandemic, in which prophylactics show little to no effectiveness, these products would give
humanity an edge over the virus. As punctuated by the current extent of the COVID-19
pandemic, such an edge could potentially save millions of jeopardized lives against the onslaught
of a dramatically mutated virus strain.
Research on combating IVA spans a variety of targets. This review focuses on the essential
M2 proton channel (M2A), a critical component of the virus’s infection cycle. M2A acidification
inside endocytic organelles initiates the release of viral genetic material into the host cell (Figure
1.1), making inhibition of M2A an effective means to prevent IVA from replicating and the
infection from progressing.5,6 Because the purpose of M2A inhibition is to block proton flow
through the channel, understanding the mechanism of proton transfer is important. At high pH,
the His37 tetrad has, at most, 2 of the residue side chains protonated, and the channel remains in
the closed position (Figure 1.2, left). The closed conformation is further stabilized by a
hydrogen-bonding network formed among the Trp41 residues.7 As the pH drops to be acidic, a
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third residue becomes protonated, and the channel activates to the open position (Figure 1.2,
right).8

Figure 1.1. Infection cycle of IVA in a host cell.

Figure 1.2. Acid activation mechanism of the M2A channel.
Further study of M2A through NMR and X-ray crystallography has failed to conclusively
determine the mechanism of activation.9 However, the leading model at the time of this writing
suggests that electrostatic repulsion among the 3-4 positively-charged His37 residues forces the
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C-terminal side of the channel to spread open.10 According to the Grotthuss mechanism, proton
transfer then proceeds through a lattice of water molecules without changing the protonation
state at the His37 cluster.11 The primary goal in inhibiting M2A, then, must be to prevent access
of hydronium to the channel interior and particularly to the His37 cluster.
M2A is a known target for the adamantane-containing compound amantadine (1adamantylamine, Amt), in which the amine binds the S31 site and the homotetracycle is
stabilized by hydrophobic interactions with the V27 tetrad. In this position, the adamantane
disrupts water flow transfer through the channel (Figure 1.3, left).12,13 By 2005, however, Amt
resistance became nearly universal across all strains via an S31N mutation of the channel that
flipped the Amt to an up-facing orientation, replacing the stabilizing influence of valine with the
less available glycine and allowing water to flow, barely inhibited, around the compound (Figure
1.3, right).14 This development led the CDC to recommend against prescribing adamantanes as
anti-IVA agents.15

Figure 1.3. Amantadine binding position in M2A. The wildtype IVA M2A channel is shown as
green ribbons (the front being removed for clarity) and the amantadine carbons as orange spacefilling spheres (left), and the M2A-S31N mutant is shown with the channel depicted by thin
tubes (the front and back being removed for clarity) and the amantadine carbons by a green balland-stick model (right).
Since then, several groups have been performing research toward developing novel M2Ainhibitory drugs, focusing on amantadines, rimantadines, and other adamantyl derivatives, as
well as a number of other moieties. Predictably, the numerous trial compounds tested in that time
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have varied to many degrees in their capacity to block M2A, with some succeeding quite well
while many showed little to no activity. A better understanding of the similarities among
successful compounds and the differences between successful and unsuccessful compounds, both
of which are explored herein, could serve to narrow compound-search parameters in future
M2A-inhibition research.
Amt derivatives most often form from N-substitutions, though sometimes substituents,
especially hydroxyl or methyl groups, are added to the ring itself.16 Observation of a
pharmacophore for inhibitors (Figure 1.4, A) within the M2A-S31N mutant reveals that the
bulky ring system is able to find a relatively stable pocket within the hydrophobic G34 cavity,
while the amine forms hydrogen bonds with the N31 carbonyl cluster.17 The foot group can be
altered in a number of ways to better suit the conditions of the M2A system (Figure 1.4, B).18
The aryl body group is further capable of acting as a hydrogen bond acceptor from the N31
amide cluster, either through the π orbitals or through O, N, or S substitution for a ring carbon.19
Finally, the aliphatic or aryl head group is able to form stabilizing hydrophobic interactions with
the V27 cluster. It should be noted that while this general design has been confirmed through
A

B

Figure 1.4. Design indicators and customizability of M2A-S31N inhibitors. (A) Pharmacophore
of M2A-S31N Inhibitors. (B) Customizability options of foot scaffold and aryl body group.

6

X-ray diffraction to be oriented, like Amt, in the head-up position in the S31N mutant, the same
orientation may not apply universally.17
Moving away from the strict Amt structure, many other opportunities for modification arise,
allowing for fine-tuning of promising anti-influenza candidate drugs. Rimantadine derivatives
can also take advantage of substitution off of the additional methylene bridge, which usually
consists of another amine group that may or may not form a cyclized system with the primary
amine. Similar derivatives can be formed by substituting Amt with other bulky ring-amine
structures, such as derivatives of pinanamine, cyclooctylamine, spiropiperidine, and azocane.5,20
Substituted phenyl-amine systems may also serve as a viable alternative scaffold to Amt.21 Some
promising activity has also been observed from linear polyamines, though they were excluded
from this comparative study because their targeting of significantly different regions of M2A
makes direct comparisons unmeaningful.22
Though a vast library of compounds can be found focusing on the moieties shown in Figure
Amantadine structures

1

2

3

4

Non-amantadine structures

5

6

7

Figure 1.5. Parent compounds selected for comparison.

8

7
1.4, Figure 1.5 shows several parent compounds that were chosen for the comparative analysis to
follow.5,16,17,20 Given the size constraints of M2A and the alternating hydrophobic and
hydrophilic sections of its protein structure, even small changes can have a significant effect on a
compound’s efficacy. These compounds were compared with some of their derivatives as well as
each other to identify factors that may provide better inhibition of M2A.
General selection criteria and synthesis techniques
Depending on the purpose of a specific study, several selection criteria were used. Studies
focusing on design, synthesis, and in vitro or in vivo physiological effects often based their
compound designs on a pharmacophore, such as that shown in Figure 1.4. While studies focusing
on in silico techniques could form a compound list the same way, they most often employed
online compound libraries. These groups formed learning sets on known inhibitors, such as Amt
or promising candidates from recent studies, and searched for other compounds with similar
therapeutic properties, which could show potential for repurposing a compound as an antiinfluenza drug.
Some standard techniques to synthesize antiviral compounds are demonstrated in Figure 1.6.
Formation of the functional structure, while rarely including very complicated techniques, can
involve any number of common organic reactions, including substitution, cyclization, and
reduction, as shown. Once the functional structure is formed, most of the reactions involved in
these syntheses center around amine alkylation of an Amt or similar scaffold. Derivatives of Amt
and other bulky, amine-containing scaffolds can be used to vary the structure and can be
synthesized as needed, though most scaffolds and many of their derivatives are readily available
commercially. After synthesis, compounds were characterized by 1H-NMR, 13C NMR, and mass
spectrometry.

8

Figure 1.6. Example synthetic route to potential candidates for M2A-S31N inhibition.
Determination of antiviral properties
Channel inhibition was tested quantitatively by measuring conductance in a two-electrode
voltage clamp (TEVC) assay using a frog oocyte with expressed M2A-S31N channels. Positive
and negative baselines were established, following which conductance was measured after a 2
minute incubation period in a 100 μM solution of compound at pH 5.5. Inhibition was calculated
as a percent of conductance reduction relative to the control values. The measurements were
reported as the average of 3 assays performed with different oocytes. In general, block of greater
than 75% was considered good for this study, and block of less than 50% was considered bad.
Plaque reduction assays were used to determine the half maximal effective concentration
(EC50) of compounds. Plaque assays were performed with MDCK cells infected with IVA-H1N1
possessing the M2A-S31N mutation, which were soaked in varying concentrations of the
compounds for 45-72 hours. Plaque formation was measured as a titrated value of PFU/mL at
several time intervals over the course of the assay. The EC50 was reported as the concentration at
which plaque formation was reduced by 50% according to a best-fit growth curve relative to a
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control with no compound. All assays were performed in duplicate. Ideally, EC50 concentrations
would be well into the sub-micromolar range.
To determine the 50% cytotoxic concentration (CC50), MDCK cells at 50,000 cells/mL were
soaked in an antibiotic growth medium for 24 hours in a 96-well cell culture plate. After the
growth period, fresh medium containing varying concentrations of compound was added to the
cells. After a 48-72 hour incubation period, the wells were stained with a colored or luminescent
medium, and the absorbance was measured and normalized against wells containing cells only.
CC50 was reported as the concentration at which absorbance was at 50% according to a best-fit
dose response curve with variable slope. The therapeutic index (TI) was then calculated by
dividing the CC50 by the EC50 to estimate the window of therapeutic clearance. Values for TI
greater than 100 were considered good.
Compounds were introduced into mouse liver microsomes to test their physiological stability.
Stability was measured as intrinsic liver clearance to determine removal of the compound by the
liver. The stability was reported as the compound half-life (T1/2) in minutes.
Comparison of chosen compounds
Derivatives of the parent structures 1-4 were chosen for comparison of M2A-S31N
inhibition, efficacy, cytotoxicity, therapeutic index, and liver microsome stability, as available.
Compound series 5-8 were chosen as examples of non-Amt scaffold structures for comparison of
efficacy and toxicity, with compounds 7 and 8 being chosen for comparison with Amt in wildtype IVA. The parent structures and their derivatives can be found in Table 1.1 along with the
available data for each as well as relevant data for Amt. Most structures can be thought of as a
scaffold foot group, an aryl body group, and a hydrophobic head group. Derivatives differed
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from their parent structures mainly in functional -OH groups on the scaffold and the size and
functionality of the aryl and head groups.
Table 1.1. Compounds and derivatives for comparison of M2A S31N block, efficacy against
IVA H1N1 M2A S31N, cytotoxicity, and liver stability.
TEVC assay
(% inhibition)
M2A-S31N

EC50 (μmol/L)
H1N1-S31N

CC50 (μmol/L)
MDCK cells

Therapeutic
Indexa

T1/2
(min)

1

91 ± 3

N.T.

N.T.

N.T.

N.T.

1a

90 ± 3

N.T.

N.T.

N.T.

N.T.

1b

59 ± 3

N.T.

N.T.

N.T.

N.T.

1c

90 ± 2

1.2 ± 0.2

59.3 ± 2.6

49

N.T.

1d

87 ± 1

N.T.

N.T.

N.T.

N.T.

1e

84.6 ± 1.2

2.1 ± 0.2

80.5 ± 5.5

38

N.T.

1f

78.7 ± 1.3

2.5 ± 0.8

65.2 ± 5.7

26

N.T.

2

90.3 ± 3.4

0.3 ± 0.1

100

333

1.0

2a

82 ± 2

N.T.

N.T.

N.T.

N.T.

2b

81 ± 4

0.5 ± 0.2

30.6 ± 5.0

61

N.T.

2c

85 ± 8

0.1 ± 0.04

> 200

> 2000

N.T.

2d

78 ± 6

N.T.

N.T.

N.T.

N.T.

Compounds

11

2e

86.1 ± 1.2

12.16 ± 1.11

19.5 ± 2.0

1.6

N.T.

3

76 ± 3

2.9 ± 0.8

123.2 ± 8.6

42

>145

3a

65 ± 4

1.1 ± 0.2

238.1 ± 2.1

216

>145

3b

79 ± 3

1.0 ± 0.1

70.2 ± 3.6

70

24.5

3c

75.6 ± 1.2

0.9 ± 0.1

317.4 ± 12.0

353

>145

3d

72.6 ± 1.4

0.6 ± 0.1

43.1 ± 2.8

72

9.1

3e

56.6 ± 1.3

3.1 ± 0.3

380.7 ± 24.9

123

100.8

3f

48.3 ± 0.5

5.1 ± 0.6

363.7 ± 18.3

71

N.T.

4

74 ± 4

N.T.

N.T.

N.T.

N.T.

4a

86 ± 2

N.T.

N.T.

N.T.

N.T.

4b

81 ± 5

N.T.

N.T.

N.T.

N.T.

4c

83 ± 4

N.T.

N.T.

N.T.

N.T.

5

N.T.

77.3

274.1 ± 58.7b

3.5

N.T.

5a

N.T.

> 150

549.6

< 3.7

N.T.

5b

N.T.

> 145

494.9 ± 30.6

< 3.4

N.T.

5c

N.T.

15.4

284.1 ± 35.3

18

N.T.

12

6

N.T.

> 170

452.9 ± 27.8b

< 2.7

N.T.

6a

N.T.

28.1

> 900b

> 32

N.T.

6b

N.T.

18.8

> 850b

> 45

N.T.

7

N.T.

0.5c

N.T.

N.T.

N.T.

8

N.T.

0.3c

N.T.

N.T.

N.T.

Amt

N.T.

0.3c

> 1000

> 3333

N.T.

aValues represent the quotient of mean CC over mean EC as an indicator of the therapeutic window. Values over 100 were
50
50
considered good. bTested with CEM (human acute lymphoblastic leukemic) cells. cMinimum inhibitory concentration against
IVA-WT. N.T. = not tested.

A lack of availability of truly analogous compounds made some comparisons difficult. For
instance, the above comparison between 1 and 1a, among many others, lacks conclusiveness as
the only example found. The same can be said of the uniqueness of both the body and head
groups of 1b. A summary of several available observations is discussed below. Because data on
M2A S31N inhibition was ubiquitously available for all compounds in series 1-4, whereas other
data was unavailable for many compounds, this summary will first focus on inhibition alone and
then move to considerations of the efficacy, toxicity, and stability of the compounds.
Of the compounds chosen, 1 with its derivates 1a-d, 2a-d, and 4 with its derivatives 4a-c
were studied by Musharrafieh and coworkers;16 1e-f, 2 with its derivative 2e, and 3 with its
derivatives 3a-f were studied by Hu and coworkers;17 5 with its derivatives 5a-c and 6 with its
derivatives 6a-b were studied by Kolocouris and coworkers;23 and 7 and 8 were studied by
Yasushi Togo as well as Beare and coworkers.20,24
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Comparison of head groups
Series 1-4 contain head groups, while series 5-8 focus primarily on their foot groups. Of the
first four series, the head groups are primarily phenyl homocycles, thiophenes, halides, and nonaryl heterocycles, respectively. Comparing inhibition of all four series to each other, the phenyl
homocycle and thiophene compounds both contained several compounds that exhibited M2AS31N inhibition above 90%, while none of the compounds of series 3 showed inhibition over
80% and series 4 contained only 4a that performed well with 86% inhibition. Judging from these
general observations, the best head groups for anti-M2A-S31N activity are phenyl and
thiophenyl groups.
Of the phenyl homocycles, the unsubstituted phenyl and cyclohexyl rings (1 and 1a,
respectively) performed very well, as did the methyl thioether (1c) and chlorine (1d), both of
which were located on the α-carbon relative to the bridge. In contrast, the methyl ether (1b) fared
particularly poorly, as was supported to a lesser degree by 2b and 2c. Between 1 and 1a, only the
aromaticity of the head group was different with equal inhibition, suggesting that the aromaticity
of the head group played little part in the inhibitory effect of the compounds. Of course, the
greater flexibility in a cyclohexyl vs phenyl ring could also play a role in the strength of
hydrophobic interactions within the tight confines of the M2A-V27 cavity, but this is hard to
support with any certainty without further examples or molecular dynamics simulations.
Comparing the compounds with thiophenyl head groups, there were no dramatically poorperforming compounds. As with compounds 1 and 1a, the unsubstituted α-thiophenyl head group
(2 and 2e) was a top performer even with different body groups, while ether-substituted head
groups (2b and 2c) performed more poorly. However, observation of 2a and 2c seems to suggest
a small helping factor from the methyl ether, though the large uncertainty in the inhibition of 2c
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renders that conclusion dubious at best. Interestingly, though, 2d showed a stark contrast to 1d,
as the chloro-substituted head group performed rather poorly. Owing to the behavior of the etherand chloro-substituted groups, the thiophenyl head group, with its higher electron density, may
be more susceptible to the influences of electron-donating and electron-withdrawing groups than
the more stable phenyl head group despite the aromaticity of the ring seeming not to matter. The
effect of positioning the halide substituent on the alpha-carbon relative to the bridge (1d and 1f)
versus the beta-carbon (2b and 2c) was unable to be determined within the sample group,
though.
The simple halide head group on the thiophenyl body group on 3 and 3b performed
comparably to the halo-substituted thiophenyl head group in 2d despite its significantly different
position on the molecule and, necessarily, within M2A. Comparing 3 with 3b and 3a with 3c, the
iodide substituent averaged higher than the bromide and was less affected by alcohol substitution
on the foot group. Comparing 3 with 3e and 3f, with 3 having the sulfur at the alpha position to
the bridge between the foot and body groups and the bromide on the beta carbon, 3e having the
bromide moved to the gamma carbon, and 3f having the sulfur on the beta carbon and the
bromide on the gamma carbon, both 3e and 3f showed dramatic decreases in channel inhibition.
The 4 series of compounds contained only two head groups: azepane in compounds 4, 4a,
and 4c, and azocane in compound 4b. Between the analogous compounds 4 and 4b, the bulkier
azocane group displayed higher M2A inhibition, as could be expected for a homocycle
interacting within a hydrophobic cavity, size constraints notwithstanding. Azocane’s extra degree
of freedom may also have allowed it to assume a better fit to interact with the M2A residues
more efficiently. However, the margins of error between the two compounds overlapped too
much for this to be considered a definitive result.
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Comparison of body groups
Out of the compounds in series 1-4, most of the chosen compounds had 2-azafuran (1, 1a,
1c-d, 2-2d), thiophene (1e-f, 2e, 3-3f), or pyridine/pyrazine (4 series) body groups. Of these, all
of the 2-azafuran compounds exhibited moderate to good block, as did the thiophene compounds
except those with only halide head groups. The pyridine body groups performed only moderately
except with the addition of an alcohol on the foot group.
Between 1 and 1b, the thiadiazole body group, rather than the ether on the head group, was
probably the main factor that decreased the potency of 1b. Because there was no direct analogue
available for either the body or head group of 1b, a definitive conclusion was difficult. However,
considering that the methyl alpha ether on the head group 2b caused a loss in block of only 9%
compared to 2, the difference of 32% block between 1 and 1b suggests that the same addition
was not to blame for the majority of the difference.
Direct comparisons of the 2-azafuran and thiophene body groups were possible by comparing
1d with 1f and 2 with 2e. In both cases, the thiophene body group performed slightly lower in
M2A inhibition than 2-azafuran. This pattern may indicate that the higher aromaticity afforded
by the pyrrolic nitrogen and furanic oxygen may be beneficial compared to the lower aromaticity
of the thiophenyl sulfur. In contrast, though, this trend is the opposite of that seen in the pyridine
and pyrazine body groups. In comparing 4 and 4c, the less-aromatic pyrazine outperformed the
higher aromaticity of pyridine, casting doubt on aromaticity as a significantly contributing factor.
Another possible trend that encompasses all three comparisons is that the number of hydrogenbond acceptors, rather than the aromaticity, is the driving force for the increased M2A inhibition.
The position of the body group within the N31 cluster supports the likelihood of this trend, as the
amide side chain is capable of both accepting and donating hydrogen bonds. Because the amide
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carbonyl accepts hydrogen bonding from the Amt nitrogen, a hydrogen bond could easily form
between the amide nitrogen donor and any hydrogen-bond acceptors in the compound’s body
group. Such a hydrogen-bonding network has the potential to be enhanced by multiple acceptors,
either due to bonding flexibility or through interactions with both the A30 and N31 residues,
which are separated by about the same interspatial distance as the N-N distance in pyrazine.
Comparison of foot groups
The effect of a tertiary alcohol on the foot group is somewhat inconclusive. Comparison of 2
with 2a and 3 with 3a, both showed a fairly significant decrease (8.3% and 11%, respectively) in
the compounds’ inhibition of M2A-S31N. Doing the same with 3b and 3c showed a smaller
decrease (3.4%), suggesting that the iodide head group was less affected than the bromide.
However, comparing 2b with 2c and 4 with 4a both show their inhibition increase (4% and 12%,
respectively) with the addition of the alcohol. A conclusive argument cannot be made from a
split among only five comparisons, especially with 2 and 2a-c having the same body group and
basic head groups. The uncertainty in 2b, 2c, and 4b are large enough to make comparisons of
their inhibition less meaningful; however, the large TI difference between 2b and 2c support the
same conclusion without uncertainty issues, lending credence to the conclusion that the -OH was
beneficial in 2c. Further observation of the structures of these two groups might indicate that the
combination of the foot alcohol group with a larger head group is beneficial where the alcohol
combined with a smaller head group is detrimental.
Compound 3d was analogous to compound 3 with one of the C—N-adjacent adamantyl
methylenes replaced with an ethylene. 3d averaged slightly lower than 3, though their margins of
error overlapped. Compound 3 also stands far ahead of 3d when considering cytotoxicity and
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liver stability, confirming that the normal, highly symmetrical structure of the adamantyl ring
system stands out over the expanded structure in terms of drug candidacy.
Comparison of non-amantadine structures
While the compounds in series 5-8 all have non-amantadyl structures, all but compound 8 are
very similar. Series 5 comprises cyclized rimantadine derivatives, series 6 comprises
spiropiperidine derivatives of Amt, and compound 7 is a spiropyrrolidine derivative of
rimantadine. Compound 8, cyclooctylamine, is presented in its own group as the only nonadamantane scaffold for comparison with Amt.
Of series 5 and 6, all of the compounds exhibited very low cytotoxicity. However, they also
all displayed very low efficacy, causing all of their TI values to plummet. Interestingly for both
series, a small substituent on the nitrogen was beneficial to cytotoxicity but detrimental to
efficacy, but as the nitrogen’s substituent was extended, the efficacy was greatly enhanced.
Unfortunately for series 5, the cytotoxicity also plummeted with the growing side chain. The
same may be true for series 6, but the cytotoxicity values, which had efficacy values approaching
those in M2A-S31N that were comparable to Amt in M2A-WT, were large enough that the
decrease may still have been acceptable. Of course, different nitrogen substituents could solve
the cytotoxicity and efficacy problems, as the comparison in this sample set is far from
exhaustive with only alkyl side chains considered.
Compounds 7 and 8 were compared directly with Amt. Only the efficacy was quantitatively
provided for both compounds—showing values comparable to Amt—though compound 7 was
reported to have no toxic or liver-damaging effects in human trials.24 As for compound 8, while a
flat representation looks completely different than Amt, its flexible, eight-carbon ring folds to fill
space very much like amantadine’s rigid, ten-carbon ring system, allowing it to behave in much
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the same way. The high efficacy and purportedly low toxicity of these compounds makes them
possible scaffolds as well.
Efficacy, cytotoxicity, therapeutic index, and liver stability
Series 4 and compounds 7 and 8 had no EC50 or CC50 data given, and series 1, 5, and 6
lacked any compounds with a TI greater than 50. Of series 2, 2 and 2c showed high TI (333 and
over 2000, respectively), with 2c being the only compound in this study with a TI over 1000,
putting its drug candidacy against M2A-S31N in a comparable position to Amt’s drug response
against M2A-WT. Compound 2 was quickly removed from the list of good compounds, though,
because despite its high TI, its liver stability was extremely low, indicating that it would be
unlikely to fare well in in vivo testing. Series 3 contained 3, 3b, and 3c that exhibited good M2S31N inhibition with 3a and 3d also showing decent inhibition, and it contained 3a, 3c, and 3e
that all exhibited good TI (216, 353, and 123, respectively). Compounds 3b and 3d were
removed from consideration because of their lower TI (70 and 72, respectively).
Of the four compounds—2c, 3a, 3c, and 3e—remaining for comparison of best traits, the
series 3 compounds had microsomal liver stability values given. Of these, 3e was the least likely
candidate; though it exhibited the highest CC50 (380.7 μmol/L) of series 1-4, its EC50 (3.1
μmol/L) was relatively high and its rather high stability (100.8 min) was still somewhat low
relative to other candidates. Compounds 3a and 3c both exhibited higher TI than 3e; though they
displayed only borderline good EC50 values (1.1 and 0.9 μmol/L, respectively), they shared the
highest stability (>145 min) in the study. Unfortunately, the liver stability of 2c was unavailable.
Because the effects of a scaffold alcohol group on M2A inhibition were inconclusive, its
effects were examined by other data. Of the ten compounds with alcohols in their foot group,
efficacy and toxicity data were available for seven (1e, 1f, 2c, 3a, 3c, 3e, and 3f), and
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microsomal liver stability was given for three (3a, 3c, and 3e). EC50 and TI varied wildly among
the seven compounds, but the CC50 values, interestingly, were all the highest reported in their
respective groups. The liver stabilities of 3a and 3c were matched only by 3, though, due to their
values only being listed as being higher than the time limit of their particular study, a
comparative analysis within those three compounds is impossible with current data. On the other
hand, 3e, a conformational analogue of 3a, showed that the position of the bromide head group
was indeed significant in terms of stability and efficacy in addition to channel inhibition.
Conclusions
Thirty-three compounds, tested previously by several research groups for M2A inhibition,
were compared in an attempt to determine properties that increase or inhibit their efficacy as
potential antivirals. For compound series 1-4, variations in the adamantyl foot groups, aryl body
groups, and cyclic head groups were considered. For series 5-6, Amt derivatives with only an
adamantyl foot group and an attached cyclic or spiro group were considered. Compounds 7 and 8
were compared with Amt in anti-M2-WT efficacy as other potential antiviral scaffolds.
The phenyl, cyclohexyl, thiophenyl, and azocanyl head groups by far performed the best out
of series 1-4. While oxygen was relatively unwelcome in the head group, sulfur fared much
better. Halide substitution on the head group was benign in some cases and harmful in others, but
it never appeared to be helpful and should probably be avoided. However, some of the
compounds in series 3, the head group of which was simply a halide, displayed very promising
test results even though their M2A current inhibition was relatively low. Aromaticity of the head
group appeared to make little to no difference, though bulkier head groups seemed to perform
better. From these observations, the best head group would likely be a large, unsubstituted ring
without restraints to its homo- or hetero-cyclic nature or its aromaticity.
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The best body group was found to be an aryl heterocycle with 2 hydrogen-bond acceptors.
The body groups that performed the best in this study were 2-azafuran and pyrazine. The foot
group was tested with an alcohol group attached to a tertiary carbon and with the ring partially
expanded. The alcohol group gave mixed results, but it appeared to be beneficial in conjunction
with a large (substituted or larger than 6-membered) head group and disadvantageous when
paired with a smaller head group. Further studies on the effect of the alcohol group would be
beneficial to optimizing anti-IVA drug development. Ring expansion of the adamantane scaffold
was detrimental in channel block, cytotoxicity, and liver stability; as such, the unmodified
adamantyl moiety—alcohol substitution notwithstanding—was considered to be the best scaffold
for the foot group for compounds containing an adamantane-like group.
While the rimantadine derivatives in series 5 showed dramatically worsening cytotoxicity
with increasing side chain size, the spiropiperidine derivatives in series 6 seemed better suited to
substitution. As only alkyl side groups were considered in this sample set, though, both scaffolds
warrant tests with other body groups. Finding effective body groups for the spiropiperidine
scaffold may be more difficult, however, due to the constrained geometry. Compounds 7 and 8
both showed efficacy comparable to Amt against M2-WT, showing that these two scaffolds have
similar capabilities to Amt in wild-type IVA. Because the four scaffolds in series 5-8 present
unique structures and geometries allowing for different customization options, they should be
considered for development starting with similar modifications as those seen for Amt in the best
practices listed above and optimizing from that point.
Future testing should be performed to refine available data of certain key points highlighted
through this study. While azocane, the largest head group, performed well, no rings of higher
than eight atoms entered the sample set, so research into larger rings should be performed to
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determine optimal head group size. Series 4 compounds, particularly 4a, should receive further
testing for efficacy, toxicity, and, if available, microsomal liver stability to enhance comparisons
further than only M2A current block, which by itself only contributes a small part to a holistic
comparison. Compounds 3a and 3c—the most promising compounds in the study—should be
strongly considered for proceeding into the next stages of drug development, as should 2c
pending stability testing.
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Abstract
New M2 blockers effective against the ubiquitous amantadine-resistant S31N M2 mutation in
influenza A are needed. Six copper complexes, 2, 4, 6, 8, 9, and 10, were synthesized and found
to block both wild type and S31N M2. Free Cu2+ also blocks M2-S31N but not S31N/H37A. The
copper complexes do not block M2-H37A (either S31 or S31N). The complexes were effective
against three influenza A strains in cell-culture assays, but less toxic to cells than CuCl2. For
example 4, Cu(cyclooctyliminodiacetate), which was stable at pH > 4 in the buffers used, had an
EC50 against A/Calif/07/2009 H1N1 of 0.7 ± 0.1 μM with a CC50 of 147 μM (therapeutic index,
averaged over three strains, 67.8). In contrast, CuCl2 had an EC50 of 3.8 ± 0.9 μM and CC50 of 19
μM (therapeutic index 5.0). Because M2-H37 is highly conserved, these complexes show
promise for further testing as drugs against all strains of influenza A.
1. Introduction
The release of ribonucleoproteins from M1 upon fusion of the influenza A envelope to the
endosomal membrane and protection of nascent hemagglutinin from premature acidification in
the trans-Golgi of infected cells are both mediated by the viral proton transporter, M2.1,2 Native
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(WT) M2 is a well-established antiviral target for the M2 channel blockers amantadine and
rimantadine,3-6 but the M2-S31N and other nearby mutations, (L26F, V27A/T/S, A30T, and
G34E) are known to cause insensitivity to amantadine in vitro.7,8 Because the S31N mutation is
now nearly universal in human infections,9 amantadine and rimantadine are no longer useful
therapeutics.10 Several attempts have been made to identify variants of these drugs and others
that could block the S31N mutation and/or other amantadine resistance mutations. For instance,
isoxazole-adamantane11 and pinanamine12 compounds effectively block M2-S31N, spiranamine
blocks M2 L26F, V27A, and WT,13 and benzyl substituted amantadines are active against both
the WT and S31N mutant.14 However, they are all limited in the scope of M2 variants they block.
This led us to explore an approach using metals that could, in theory, target all functional forms
of M2, perhaps in most or all amantadine-sensitive and -resistant strains.
The homotetrameric M2 channels are exquisitely selective for transport of H+ over other
monovalent ions5 due to a tightly-packed cluster of His37 side chains at the narrowest passage in
the channel.15,16 This residue is highly conserved in inﬂuenza A (99.97% identical in all isolates
found in GenBank). The M2 current in transfected oocytes was found previously to be blocked
by 250–500 μM Cu2+, with block eliminated by mutation of M2-His37 to Ala.17 Cu2+ and other
divalent cations Ni2+, Pt2+, Cd2+, Mg2+, Mn2+, and Zn2+ caused only partial, readily reversible
block at 1–2 mM concentrations. Using triangulation of paramagnetic shielding eﬀects in solidstate NMR, Cu2+ was found to bind in the core of the His37/Trp41 cluster located within the
homotetramer.18
Metals have a long history of medicinal applications, beginning primarily in 1978 with the
approval of cisplatin as an anticancer drug.19 While much medicinal metal-complex research
attempted to mimic the anticancer success of cisplatin,20-24 many uses for metal complexes have
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been discovered for other conditions. Gold, as a noble metal, was discovered to be effective in
controlling the progression of arthritis as early as 1934,25-27 vanadium aided patients with
diabetes as an insulin-mimetic drug,28 and zinc was researched as a chemokine receptor
antagonist with anti-HIV activity and as a stem-cell mobilizer.29
A great deal of copper-related medicinal research centered around chelation therapy to
remove excess copper from the body to treat Alzheimer’s and Wilson’s diseases,30,31 including,
interestingly, zinc chelates32 and a complex anion of molybdenum.33 Non-removal applications
existed in the literature as well, however, as evidence was shown that at least one potential
Alzheimer’s disease drug acted as a copper transporter to correct the faulty copper homeostasis
in the brain rather than removing the copper (Bush 2008, Ferrada 2007, Atwood 2000, Treiber
2004),30,34-36 and a copper(II)-bis-histidine complex was utilized to deliver copper to human
serum albumin, counteracting deficiencies in Menkes disease patients.37 Recently, copper
complexes have also been developed as anti-inﬂammatory, antibiotic, and chemotherapeutic
agents.38-45 Though in vivo side-reactions with non-target binding sites must be especially
considered during drug development for metal complexes,46 treating patients with metal-chelate
complexes can mitigate that danger.37
Although intracellular copper levels are tightly regulated,47,48 daily dietary intake limitations
are modest,49 such that the bodily exposure to the copper content from moderate doses of such
therapeutics by traditional routes can be expected to be well tolerated. By derivatizing the amines
of known M2 blockers, amantadine (Amt) and cyclooctylamine (CO), to form the iminodiacetate
or iminodiacetamide, we have synthesized Cu2+ containing complexes and characterized them by
NMR, IR, MS, UV–vis, and inductively coupled plasma mass spectroscopy (ICP-MS). These
can be compared with other small molecule inhibitors of M2-S31N transport.50,51 Because Cu2+
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binds strongly to imidazole, it was suggested that the Cu2+ complexes also block M2 through
His37-imidazole binding. In addition, the His37 cluster is highly conserved in nature,52 making it
a prime target in the M2 channel.
Drawing from the observation that divalent cations, particularly copper, block M2 current17
binding in the His37-Trp41 side chain quadruplex,18 divalent copper complexes of Amt were
synthesized and found to be effective influenza A inhibitors with reduced cytotoxicity compared
to CuCl2. The copper ligands developed were based on Amt and the lesser-known, equally
effective M2-WT blocker, CO,53,54 and extended via the amine with the functional groups
iminodiacetate or iminodiacetamide. Six Cu2+ complexes (Figure 2.1) were synthesized and
characterized using NMR, IR, MS, UV-Vis, and ICP-MS. Proton current block and H37
specificity were tested in two electrode voltage-clamp studies, and cytotoxicity and efficacy were
tested in cell cultures. Three-day solution stability studies were performed with the Amt- and
CO-containing complexes 2, 4, 6, and 8 in each of water and both biological testing media.
Complexes 2 and 4 in particular stood out as promising examples of metal complexes in the
arena of M2 inhibition.

2
4
6
8
9
10
Figure 2.1. Copper complexes with the functional groups iminodiacetate or iminodiacetamide
extended via the amine to either AMT or CO.
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2. Materials and methods
2.1. Instruments and materials
Solvents and compounds were used as received by commercial suppliers. Purity of tested
complexes was veriﬁed by 1H-NMR, ICP and elemental analysis and found to be ≥ 95%. The
copper complexes were usually accompanied by two water molecules, but in some cases the
number of waters varied between batches and was quantiﬁed before running assays with the
complexes. The IDAA complexes contained NaCl, which was quantiﬁed before doing assays.
NaCl was veriﬁed by x-ray photoelectron spectroscopy. The hydrated complexes lost water
during the melting point measurements but did not melt.
1

H and 13C NMR spectra were recorded on Varian 300 and 500 MHz multinuclear FT-NMR

spectrometers. Proton chemical shifts were reported in parts per million (δ) with reference to
tetramethylsilane (TMS, δ 0.0 ppm) or their respective solvent peaks. Mass measurements were
done on an Agilent model G1969A LC/MSD TOF mass spectrometer. IR spectra were collected
on a Thermo Scientific Nicolet iS5 FTIR using Nujol. Elemental analysis was done by M-H-W
Laboratories. UV-Vis studies were done on a HP 8453 spectrophotometer. Copper contents were
confirmed by inductively coupled plasma mass spectrometry done on a Perkin Elmer Optima
2000 OES spectrometer. X-ray diffraction data comprising φ- and ω- scans were collected using
a MACH3 four circle diffractometer coupled to a Bruker Apex II CCD detector with a BrukerNonius FR591 rotating anode X-ray source producing Cu Kα radiation (λ = 1.54178 Å). X-ray
photoelectron spectroscopy (XPS) analyses were performed by using a Surface Science SSX-100
X-ray photoelectron spectrometer.
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2.2 Compound and complex synthesis
2.2.1. Synthesis of N-(1-adamantyl)-iminodiacetic acid (1)
This compound was synthesized by a revised procedure from that found in the literature.55
Amantadine (9.068 g, 60 mmol) and bromoacetic acid (18.569 g, 134 mmol) were added to a
50:50 ethanolic aqueous mixture (100 mL) in a 2:1 molar ratio that was then titrated to pH = 11.5
using 12 M NaOH. The mixture was refluxed at 93 ºC for 21 h while maintaining an alkaline pH
> 11. The ethanolic aqueous mixture was extracted with diethyl ether three times (30 mL each)
to remove organic impurities. Following extraction and removal of the organic phase, the
aqueous phase was titrated to pH 3 with concentrated HCl. Slow evaporation in 50:50 EtOH:H2O
afforded the desired white precipitate. Yield: 7.847 g (49.0%). 1HNMR (500 MHz, MeOH-d4,
25ºC): δ 3.89 (s, 4H), 2.21 (s, 3H), 1.97 (s, 6H), 1.73 (t, 6H) ppm. 13C NMR(500 MHz, MeOHd4, 25 ºC): δ 170.4, 81.4, 65.4, 52.6, 46.9, 35.5, 30.1, 20.5, 12.5 ppm. HRMS (ESI): m/z calc for
C14H21NO4 + H+: 268.15; found 268.14. Selected IR frequencies (cm-1): 3364 (COOH), 1614
(CO). Decomposed at 220 °C.
2.2.2. Synthesis of Copper N-(1-adamantyl)-iminodiacetic acid (2)
Copper acetate monohydrate (0.2004 g, 1.0 mmol) was dissolved in 75 ml of methanol.
Separately, 1 as prepared above (0.6148 g, 1.0 mmol) was dissolved in 50 mL of methanol, and
the resulting solution was added to the copper acetate solution with stirring. As the solutions
were combined, the color changed from aqua to blue. After 5 minutes, 250 mL of diethyl ether
was added, and the layers were allowed to mix slowly for 5 hours. The light blue precipitate was
collected by filtration and rinsed with 125 mL of diethyl ether, which was added to the filtrate.
The process of filtering and adding diethyl ether was repeated to collect two more crops. Yield:
0.2203 g (60.2% yield of dihydrate complex). Crystals can be obtained from water by slow
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evaporation. 1HNMR (500 MHz, MeOH-d4): no compound peaks. 1HNMR (500 MHz,
MeOHd4, 1 drop TFA): δ 4.19 (s, 4H), 2.24 (s, 3H), 2.01 (s, 6H), 1.73 (t, 6H) ppm. HRMS
(ESI): m/z calculated for [Cu(C14H19NO4)∙H2O]+ : 346.07; found 346.09. Selected IR frequencies
(cm-1): 1592(CO). Elemental analysis calculated for Cu(C14H19NO4)∙2H2O: C, 46.08; H, 6.35; N,
3.84; found: C, 46.20; H, 6.38; N, 3.73. Decomposed at > 250 °C.
2.2.3. Synthesis of Cyclooctyliminodiacetic acid (3)
Cyclooctylamine (0.3956 g, 3.1 mmols) was added to a mixture of water (4 ml) and ethanol
(25 ml). Bromoacetic acid (0.8641 g, 6.2 mmols) was added. The solution was titrated to pH 11
with 12 M sodium hydroxide, and maintained at that pH. The solution was refluxed and stirred
for 24 hours. The reaction mixture was cooled to 0 °C and a beige precipitate was collected by
vacuum filtration and washed with 10 mL of ethanol. The filtrate was cooled to 0 °C and allowed
to sit for 20 minutes. The beige precipitate that formed was collected by vacuum filtration and
washed with 10 ml of ethanol. Acetonitrile (30 ml) was added to the filtrate. A precipitate
formed, was filtered, and discarded. The filtrate was allowed to sit for several days, and a beige
precipitate formed. The precipitate was collected. The combined beige precipitates were airdried, weighed 0.7097 g (79.5% of disodium compound), and produced the sodium salt of 3. 1HNMR (D2O, 300 MHz) δ ppm: 3.11 (s, 4, CH2), 2.88 (t, 1, CH), 1.59 (m, 4, CH2), 1.41 (m, 4,
CH2), 1.31 (m, 6, CH2). 13C NMR (D2O, 500 MHz) δ = 178.0, 61.1, 55.1, 28.9, 25.9, 25.6, 24.9
ppm. HRMS (ESI) m/z: calculated for [C12H21NO4 + H+] 244.15; found 244.15. Selected IR
frequencies (cm-1): 1622 (CO), 1600 (CO). Decomposed at 260 °C.
2.2.4. Synthesis of Copper cyclooctyliminodiacetic acid (4)
Copper acetate monohydrate (0.1434 g, 0.72 mmols) was added to 20 ml of methanol,
disodium cyclooctyliminodiacetate (0.2064 g, 0.72 mmols) was added to it and the solution was
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stirred for 5 minutes. As 3 dissolved, the solution became dark blue. The solution was allowed to
evaporate for several days while blue-green solid formed. When 2 mL of methanol remained, the
solid was collected by decantation, dried, and gave 0.2860 g (89.7% yield of hexahydrate
complex with 0.5 acetic acids). 1H-NMR (MeOD, 300 MHz) δ broad peaks from 3.67-1.19. 1HNMR (MeOD, 1 drop TFA, 300 MHz) δ 4.10 (s, 4H); 3.55 (s, 1H); 1.88 (b, 4H); 1.68 (b, 4H);
1.5 (b, 4H); 1.42 (b, 2H). HRMS (ESI) m/z: calculated for [Cu(C12H19NO4) + COOH + H+]
351.01; found 351.080. Selected IR frequency (cm-1): 1590 (CO). Elemental analysis calculated
for Cu(C12H19NO4)∙2.5H2O∙0.5CH3COOH: C, 41.10; H, 6.90; N, 3.69; found: C, 41.26; H, 5.63;
N, 4.01. Decomposed at > 250 °C.
2.2.5. Synthesis of Amt-iminodiacetamide (5)
Amantadine (0.3169 g, 2.10 mmol) and bromoacetamide (0.5783 g, 4.19 mmol) were
dissolved in 10 ml of DMF. Diisopropylethylamine (0.6769 g, 5.23 mmol) was added to the
solution. The reaction was allowed to stir at room temperature for two hours followed by four
hours at 115 °C. The white precipitate that formed was collected and washed with 6 ml DMF, 8
ml of water, and 4 ml of methanol. The reaction gave 0.3846 g of product (69.2%). 1H-NMR
(DMSO, 500 MHz) δ 7.97 (s, 2H), 6.99 (s, 2H), 3.09 (s, 4H), 2.00 (s, 3H), 1.56(m, 12H) ppm.
13

C NMR (DMSO, 500 MHz) δ 175.9, 55.0, 54.1, 38.7, 36.4, 29.2 ppm. HRMS (ESI) m/z:

calculated for C14H23N3O2 + H+: 266.187; found 266.185. Selected IR frequencies (cm-1):
3320(NH), 3154(NH), 1693(CO),1667(CO). Decomposed at 290 °C.
2.2.6. Synthesis of Cu(Amt-iminodiacetamide) (6)
5 (0.0907g, 0.34 mmol) was added to 20 ml of dry DMF under N2. Sodium hydride (0.0310
g, 0.78 mmol) in 5 ml of dry DMF was added to the 5 solution over a five minute period. Copper
chloride dihydrate (0.0582 g, 0.34 mmol) was dissolved in 5 ml of dry DMF and quickly added.
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The reaction was stirred overnight at room temperature under N2. THF (75 mL) was added and a
purple precipitate formed. The precipitate was filtered, washed with 10 ml of ethanol and 15 ml
of diethyl ether. The reaction gave 0.0644 g of product (37.2% yield of dihydrate sodium
chloride complex). 1H-NMR (DMSO, 500 MHz) δ ppm: no compound peaks. 1H-NMR (DMSO,
TFA, 500 MHz) δ ppm: 7.97 (s, 2H), 6.99 (s, 2H), 3.09 (s, 4H), 2.00 (s, 3H), 1.56 (m, 12H).
HRMS (ESI) m/z: calculated for [Cu(C14H21N3O2) + H+] 327.09; found 327.10. Selected IR
frequencies (cm-1): 1665(CO), 1571(CO). Elemental analysis calculated for
Cu(C14H21N3O2)∙2H2O∙2.5NaCl: C, 33.04; H, 4.95; N, 8.36; found: C, 32.96; H, 4.45; N, 8.37.
Decomposed at > 250 °C.
2.2.7. Synthesis of Cyclooctylimidodiacetamide (7)
Cyclooctylamine (0.7715 g, 6.0 mmol) and 1.6896 g (12.2 mmol) bromoacetamide were
dissolved in 20 ml of acetonitrile. Anhydrous K2CO3 1.8455 g (13.3 mmol) was added. The
mixture was stirred and heated at 60 ˚C for 16 hours and allowed to cool. The flask was
sonicated to remove any solid adhered to the glass and the tan precipitate was filtered off; the
filtrate was set aside and the precipitate was washed with water. The solid and the filtrate were
combined and heated to reflux; the solution became transparent. This solution was allowed to
cool and the resulting colorless crystals were collected by vacuum filtration. The product
weighed 0.9702 g (66.3%). 1H-NMR (DMSO, 300 MHz) δ 7.72(s, 2H), 7.17(s, 2H), 2.92(s, 4H),
2.58(m, 1H), 1.70 (m, 4H), 1.52 (m, 4H), 1.46 (m, 6H). 13C NMR (DMSO, 500 MHz) δ 173.8,
61.0, 55.6, 29.9, 26.39, 26.31, 25.5 ppm. HRMS (ESI) m/z: calculated for [C12H23N3O2 + H+]:
242.16 ; found 242.186. Selected IR frequencies (cm-1): 3317 (NH), 3163 (NH),1690 (CO), 1665
(CO). Melting point 152-154°C.
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2.2.8. Synthesis of Copper cyclooctylimidodiacetamide (8)
7 (0.8162 g, 3.4 mmol) was dissolved in 150 mL dry DMF under nitrogen. NaH (0.3094 g,
7.735 mmol) was added, and the solution was stirred for 5 minutes. Separately, CuCl2∙2H2O
(0.5983 g, 3.5 mmol) was dried in an oven for several hours at 120° C, cooled in a desiccator,
and dissolved in 100 mL dry DMF. The gold CuCl2 solution was then poured into the 7 solution.
The solution’s color started green and gradually turned dark blue. The solution was stirred at
room temperature for 16 hours under nitrogen. The solution was then removed from nitrogen and
500 mL THF was added to it. The dark blue precipitate that formed was collected by filtration,
rinsed with THF, and dried in vacuo. Yield: 0.7356 g (37.8% of dihydrate sodium chloride
complex). 1H-NMR (CD3OD, 500 MHz): broad signals. 1H-NMR (CD3OD, 1 drop TFA, 500
MHz) δ 4.00(s, 4H), 3.51(m, 1H), 1.87 (m, 4H), 1.72 (m, 4H), 1.52 (m, 6H). HRMS (ESI
negative) m/z: calculated for [CuC12H21N3O2 + H2O + OH-]: 337.11; found 337.126. Selected IR
frequencies (cm-1): 1594(CO). Elemental analysis calculated for Cu(C12H21N3O2)∙2H2O∙4NaCl:
C, 25.17; H, 4.40; N, 7.34; found: C, 24.62; H, 4.21; N, 7.13. Decomposed at > 250 °C.
2.2.9. Synthesis of Copper iminodiacetic acid (9)
This complex was previously made by a different procedure.56 Iminodiacetic acid (0.2455 g,
1.84 mmol) was dissolved in 25 ml of water and copper(II) acetate monohydrate (0.3682 g, 1.84
mmol) was added to the solution. The solution was sonicated until all of the copper acetate
dissolved. NaOH (12 M) was added to the solution until the pH reached 7. The flask was allowed
to stand at room temperature for 24 hours during which time a precipitate formed. The blue
precipitate was collected by filtration and weighed 0.2887 g (68.0% yield of dihydrate complex).
1

HNMR (300 MHz, D2O) no compound peaks 1HNMR (300 MHz, D2O, TFA) δ 3.82 (s). HRMS

(ESI): m/z calc for Cu(C4H5NO4) + H+: 194.959; found 194.95. Selected IR frequencies (cm-1):
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3169 (NH), 1590 (CO). Elemental analysis calculated for Cu(C4H5NO4)∙2H2O: C, 20.83; H,
3.93; N, 6.07. Found: C, 21.22; H, 3.77; N, 5.69. Decomposed at > 250 °C.
2.2.10. Synthesis of Copper iminodiacetamide (10)
To 25 ml of dry DMF under N2 was added 2-[(carbomoylmethyl)amino]acetamide (0.2600 g,
1.98 mmol). Sodium hydride (0.1790 g, 4.47 mmol) in 5 ml of dry DMF was added to the
solution and it was allowed to stir for five minutes. Copper chloride dihydrate (0.3379 g, 1.98
mmol) dissolved in 5 ml of dry DMF was quickly added and the solution stirred for 16 hours at
room temperature. THF (100 ml) was added to the reaction mixture and the resulting green
precipitate was collected by filtration and centrifugation. After drying under vacuum, the
remaining solid weighed 0.1866 g (23.3% yield of dihydrate complex with sodium chloride).
1

HNMR (300 MHz, DMSO) δ no compound peaks. 1HNMR (300 MHz, DMSO, TFA) δ 7.80 (s,

2H), 7.52 (s, 2H), 3.69 (s, 4H). HRMS (ESI): m/z calc for Cu(C4H7N3O2) + H+ 192.99; found
192.998. Selected IR frequencies (cm-1): 1663 (CO). Elemental analysis calculated for
Cu(C4H7N3O2)∙2H2O∙3NaCl : C, 11.89; H, 2.74; N, 10.40. Found: C, 12.32; H, 2.28; N, 9.79.
Decomposed at > 250 °C.
2.3. Stability Studies
Solutions of the complexes were made by dissolving a few milligrams of complex in 3.0 mL
of solvent to make 10 mM solutions. Complexes 2, 6, and 8 were dissolved in methanol, and 4
was dissolved in water. The solutions were sonicated and gently warmed to aid dissolution. 100
μL of each solution was then added to 9.90 mL of either water, Barth’s or simple electrolyte
medium (SEM: 148 mM NaCl, 3 mM KCl, 1.6 mM CaCl2, 0.8 mM MgCl2, 0.75 mM Na2HPO4,
0.1 mM NaH2PO4, pH 7.2 to make 100 μM solutions and the solutions were capped). UV–vis
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spectra were taken at time increments over three days at room temperature and background
subtraction of solvent was applied.
2.4. Electrophysiology
Oocytes from Xenopus laevis (Ecocyte, Austin, TX) were prepared with A/Udorn/72 H3N2,
A/Udorn/72 H3N2 M2-S31N, or A/Udorn/72 H3N2 M2-S31/ H37A mRNA and maintained at 4
°C and pH 7.4 for 72 hours, at which time electrophysiological recording was performed. Wholecell currents were recorded with a two-electrode voltage-clamp apparatus at Vm = −20 mV,
room temperature, in Barth’s solution, pH 7.5. Inward current was induced by perfusion with
Barth’s pH 5.3. Percentage block of the original inward current by 100 μM test compound or
complex was measured just before washout, which was done 8 min 50 s after drug exposure, or
upon current stabilization, for each compound or complex.
2.5. Cell culture
Influenza-sensitive Madin-Darby canine kidney (MDCK, ATCC, Manassas, VA) cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO). 1.1 g/L
of sodium bicarbonate, 10 μM Hepes, 100 U/mL of Penicillin and 100 μg/mL of Streptomycin
were added to the growth and cytotoxicity test media. Cell cultures were incubated at 37 °C in a
humidified 5% CO2 incubator. Passaging was carried out twice weekly using 0.25% trypsinEDTA (ThermoFischer Scientific, Waltham, MA). The growth medium was supplemented with
5% fetal bovine serum (FBS, Hyclone, Logan, UT).
2.6. Cytotoxicity assay
MDCK cells were seeded into the 60 internal wells of a 96-well plate at a density of 2 × 104
cells/well in 5% FBS DMEM. After 48 h, growth media was removed, and replaced with DMEM
supplemented with 1% FBS containing test complex at concentrations of 4 μM to 1 mM in 2-
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fold increments, six wells per concentration. Six wells without the test compound or complex
served as controls. The cells were incubated with the test compound or complex for 72 h at 37 °C
in a humidified 5% CO2 incubator. The crystal violet staining technique as described was used to
determine cytotoxic activity.57 After 72 h, the test medium was removed, and the cells were
washed three times with 300 μL of PBS. The cells were next fixed and stained for 10 min with
50 μL of crystal violet solution (0.03% crystal violet (w/v) in 20% methanol). The cells were
then washed 6 times with 300 μL of distilled water, before adding 100 μL of lysis buffer to the
cells for 20 min. The optical density of each well was measured at 620 nm, averaged over the set
of six wells for each concentration, and the 50% cytotoxic concentration, or the concentration of
test compound or complex that killed half of the cells was calculated using a non-linear least
squares fit in KaleidaGraph (Synergy Software, Reading, PA, USA), and are expressed as the
fitted CC50 ± SE(CC50), where the standard error of the parameter is derived from the parameter
covariance matrix for the fit.
2.7. Viral infection assay
As described previously,58 MDCK cells were seeded onto 12-mm glass coverslips at 2.4 ×
104 cells/vial in 1 mL of DMEM with 5% FBS. The cells were incubated overnight at 37 °C in a
humidified 5% CO2 incubator. The culture was washed with serum-free medium to remove
remaining FBS. SEM used in the miniplaque assay was selected for sustaining cell viability,
allowing viral infection, and having minimal UV absorbance to allow easy determination of the
complex stabilities. The EC50 for Amt was 3.4 ± 0.9 μM in SEM and 2.8 ± 0.3 μM in DMEM
against the Amt-sensitive A/Victoria/03/75 H3N2.
Two to four replicates were done at each of five to six concentrations ranging from 1 to 50
μM, and four shell vials without any added test compound or complex served as controls. Stock
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virus was thawed, treated with tosyl phenylalanyl chloromethyl ketone (TPCK) treated trypsin at
1 μg/mL, and then diluted with SEM to the appropriate dosage. The culture was inoculated with
100 μL of the solution containing activated virus, either A/Calif/07/09 H1N1, A/WS/33 H1N1,
or A/ Victoria/03/75 H3N2, and incubated at 33 °C for 16 h. Coverslips were washed with
phosphate-buffered saline (PBS), fixed with cold acetone (−80 °C), and then removed from the
shell vials. After air-drying for 30 min, the coverslips were stained with anti-IAV FITC-labeled
monoclonal antibody (Light Diagnostics #5017, EMD Millipore – now Millipore Sigma,
Billerica, MA) and incubated at 37 °C for 30 min in a humidified chamber. Excess antibody was
washed off with PBS containing 0.05% Tween20, 0.5 mM MgCl and 3.1 mM sodium azide and
distilled water. Miniplaques, defined as one or a few adjacent cells that were antibody-labeled
(considering mitotic events and neighbor infection events as single miniplaques) were then
counted with a fluorescent microscope. The 50%-effective concentrations (EC50) were obtained
by a non-linear least-squares fit using the Levenberg-Marquardt algorithm in KaleidaGraph and
are expressed as the fitted EC50 ± SE(EC50), where the standard error of the parameter is derived
from the parameter covariance matrix for the fit.
3. Results and discussion
3.1. Compound and complex synthesis and structure
Bromoacetic acid and bromoacetamide were added to Amt or cyclooctylamine to produce 1,
3, 5, and 7 (Figure 2.2). Only a weak acetate base was required to promote the coordination of
Cu> to 1 and 3. A strong base, NaH was needed to deprotonate the amides of 5 and 7 and
promote Cu2+ coordination.59 Upon Cu2+ coordination to form 2, 4, 6, and 8, neutral complexes
were formed due to the carboxylic acids and the amide nitrogens losing protons. Compounds 9
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and 10, which were identical but without the scaﬀolds attached to the imino N, were formed
from the amino diacetate or diacetamide.

Figure 2.2. Synthetic procedures for compounds 1-8.
Crystals of 2 were grown and X-ray analysis of the crystals showed ligand coordinating in a
meridional arrangement around Cu2+ (Fig. 2.3). Water molecules occupy an equatorial position
and one of the axial positions. The equatorial bonds are shorter and close to 2.0 Å, while the
axial bond is longer (2.4 Å) due to Jahn-Teller distortion. The water molecules are labile and will
exchange with stronger ligands, such as ligands containing nitrogen.60 Except for a strong
absorbance at around 200 nm, the Cu2+-free compounds, 1, 3, 5, and 7, have very little

Figure 2.3. Crystal structure (side and face views) of 2.
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absorbance (data not shown). Once Cu2+ binding to the compounds occurs, a strong absorption
band in the UV region at 250–280 nm is observed and absorption in the visible gives the
complexes a blue coloration (see the legend of Fig. 2.5 for extinction coefﬁcients).
3.2. Stability studies
UV absorption spectra of the complexes measured in water at therapy-like concentrations of 100
μM showed that 2, 4 and 8 were stable in water for three days, while 6 showed moderate
decomposition (Figure 2.4). The d-d transition produces absorption, enhanced by complexation,
at visible wavelengths that could provide similar information. However, the extinction coeﬃcient
is ∼100-fold lower than for the absorbance in the UV, so for assays at the therapeutically

relevant concentrations, we focused on UV measurements. Stability studies of the complexes in
biological electrolyte solutions showed a good degree of stability for most of the complexes. In
the SEM used for miniplaque assays, 2 and 4 were again stable for three days, but 8 showed
some reduction in absorbance and 6 fully decomposed (Figure 2.5), whereas in Barth’s all four
spectra were stable.
In the Barth’s solution used in the oocyte assays, as in SEM, 2 and 4 were stable (Figure 2.6). 6
and 8 showed changed UV-vis spectra with peak intensities being lower than they were in water.
A reduction in absorption intensity implies a change in molar absorptivity, which would occur
with the formation of a new complex. Most likely a new complex formed, potentially one with a
buffer component bound to the copper in the complex. The absorbance bands, however, did not
significantly decrease over the course of three days.
The metal complexes show good stability at pH ~7. Judging from the UV spectra of 100 µM
complexes in water titrated with HCl or NaOH, complexes 2 and 4 show stability over a pH
range from 4 to 9. In contrast, the 6 and 8 are not stable at pH below 5 or above 13. IDAA has a
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Figure 2.4. UV–Vis spectra of 100 μM
solutions of (A) 2, (B) 4, (C) 6, and (D) 8 in
water. Spectra color: blue start, orange 4 h,
green 12 h, purple 24 h, yellow 72 h.

Figure 2.6. UV-Vis spectra of 100 μM
solutions of (A) 2, (B) 4, (C) 6, and (D) 8 in
Barth’s. A spectrum of Barth’s solution was
subtracted as background. Spectra color: blue
start, orange 4 hrs, green 12 hrs, purple 24
hrs, yellow 72 hrs.

Figure 2.5. UV-Vis spectra of 100 μM
solutions of (A) 2, (B) 4, (C) 6, and (D) 8 in
SEM. A spectrum of SEM was subtracted as
background. Spectra color: blue start, orange
4 hrs, green 12 hrs, purple 24 hrs, yellow 72
hrs. Spectral bands in the UV region upon
Cu2+ binding: 252 nm (5300 abs M-1 cm-1)
for 2, 251 nm (3700 abs M-1 cm-1) for 4,
286 nm (1600 abs M-1 cm-1) for 6, and 285
nm (2800 abs M-1 cm-1) for 8. Along with
the UV band, there is a new band in the
visible region: 705 nm (220 abs M-1 cm-1)
for 2, 717 nm (100 abs M-1 cm-1) for 4, 650
nm (200 abs M-1 cm-1) for 6, and 637 nm
(170 abs M-1 cm-1) for 8. The UV
absorption with its intermediate molar
absorptivity is proposed to be due to a
ligand-to-metal charge transfer (LMCT) and
the peak in the visible is due to a copperbased d-d transition.
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very high pKa (around 17) and thus, because of the compound’s strong affinity for protons, Cu2+
is out-competed by protons at moderate pH values. In comparison, the affinity of IDA for
protons is much smaller, (with the pKa expected to be near that of acetic acid, 4.8), so a lower pH
is required for H+ to out-compete Cu2+ for the binding site in the complex (data not shown).
3.3. 1H-NMR characterization
The decomplexation at low pH was used to characterize the complexes. Due to the
paramagnetic nature of Cu2+ ions, no 1H-NMR signals or only broad peaks were visible when
Cu2+ is bound to the compounds (Figure 2.7). However, after acidifying the complexes to pH < 3,
the unbound ligand 1H-NMR signals are visible (Figure 2.8).

Figure 2.7. 1H-NMR (300 MHz) of 2 with an acetonitrile standard before acidification in
DMSO-d6. Peak assignments (ppm): 0.00 TMS, 2.07 NCCH3, 2.51 DMSO, 3.32 H2O.
3.4. Antiviral properties
Experimentally determined concentrations of CC50, as well as EC50 against two standard
strains of influenza A with the M2-S31N mutation, are given in Table 2.1. The only complex that
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Figure 2.8. 1H-NMR (300 MHz) of 2 with an acetonitrile standard after acidification with
trifluoroacetic acid in DMSO-d6. Peak assignments (ppm): 0.00 TMS, 1.63 adamantane CH2,
1.97 adamantane CH2, 2.07 NCCH3, 2.17 adamantane CH, 2.57 DMSO, 3.94 H2O, 4.18 IDA
CH2.
Table 2.1. Cytotoxicity and efficacy data for CuCl2, 2, 4, 6, 8, 9, and 10.
EC50
CC50
Compound
(µM, A/CA/07/09
(µM, S31N)
H1N1 M2-S31N)
CuCl2
19 ± 6
3.8 ± 0.9

EC50
(µM, A/WS/33
H1N1 M2-S31N)
4.3 ± 1.0

2

64 ± 7

6.9 ± 1.2

2.4 ± 0.3

4

147 ± 38

0.7 ± 0.1

2.1 ± 0.7

6

52 ± 5

4.9 ± 0.8

4.1 ± 2.4

8

180 ± 15

11.6 ± 1.1

2.3 ± 0.2

9

115 ± 9

8.2 ± 2.0

4.7 ± 1.1

10

64 ± 6

4.4 ± 0.6

7.2 ± 5.3

was more effective than the free copper in the 2009 pandemic strain (A/CA/07/09 H1N1 M2S31N) was 4. That was also the only complex that gave a CC50 over 100 µM and a sub-µM EC50
against either strain. All complexes except 9 and 10 exhibited lower EC50s than CuCl2,
highlighting the importance of the Amt and CO scaffolds on the complexes. Curiously, 8
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performed well with the highest CC50 of all the complexes and the second lowest EC50 against
the WS strain. However, the dissociation shown in the UV-Vis stability studies made meaningful
observations difficult to derive from direct comparisons to other complexes. Notably, the copperfree ligands performed similarly to amantadine in both the M2-S31N mutant and the M2-S31
WT virus (data not shown).
Experimentally determined data for M2 channel block for CuCl2, Amt, and complexes 1-10
are given in Table 2.2 as the average and standard deviation from 3 assays. The TEVC trace of
CuCl2 (Figure 2.9A) was the standard trace against which the other traces were compared, as it
Table 2.2. M2 block of CuCl2, Amt, 2, 3, 4, 6, 8, 9, and 10. All data represent the average of 3
replicates.
Compound
% Block
% Block
% Block
% Block
% Block
Fast
Total
Recovered
(H37A)
Recovered
(S31N)
(S31N)
(S31N)
(H37A)
CuCl2

18 ± 1.4

95 ± 2.8

None

19.8 ± 0.3

14.9 ± 0.2

2

10.5 ± 2.1

91.5 ± 7.8

9.0 ± 1.4

N.T.

N.T.

4

11.5 ± 0.7

90.5 ± 2.1

1.2 ± 0.3

12.0 ± 2.8

6.0 ± 1.4

6

18.5 ± 2.1

91.5 ± 4.2

7.5 ± 0.7

N.T.

N.T.

8

25 ± 2.8

66.5 ± 5.0

24 ± 0.2

26 ± 10.9

24.6 ± 14.1

9

5.9 ± 0.1

17.9 ± 2.9

1.7 ± 1.9

N.T.

N.T.

10

33.5 ± 0.7

68.0 ± 2.8

22 ± 1.4

N.T.

N.T.

Amantadine*

30.5 ± 1.3
(93.6 ± 2.6)

None
(None)

29.1 ± 1.4
(None)

N.T.

N.T.

1

6.5 ± 1.5

None

None

N.T.

N.T.

3

42.8 ± 0.6

None

33.4 ± 1.7

6.8 ± 0.4

4.5 ± 0.7

5

9.6 ± 8.3

None

5.6 ± 3.7

N.T.

N.T.

7

12.5 ± 2.5

None

6.8 ± 0.4

N.T.

N.T.

*Data in parentheses were tested against M2-S31 WT. N.T. = not tested.

43
showed a steady increase in current block with no current recovery after a compound-free rinse
solution was introduced. Complex 4 again stood out with high block (90.5 ± 2.1%) and only a
slight (1.2 ± 0.3%) recovery, and its trace (Figure 2.9B) clearly shows a fast-phase block as the
initial, almost vertical increase, and a slow-phase block as the creeping upward trend over time.
Compound 3, by comparison, showed the highest fast-phase block (42.8 ± 0.6%) but no slowphase block, and most of its block was recovered (33.4 ± 1.7%) with the introduction of the rinse
solution. This strong recovery created a characteristic “plateau” curve (Figure 2.9C) also
exhibited by Amt against both M2-S31 WT and M2-S31N, the other copper-free ligands 1, 5, and
7 against M2-S31N, and CuCl2 and the metal complexes 4 and 8 against M2 H37A. Despite its
strong CC50 and EC50 against the WS virus, 8 blocked the M2-S31N channel poorly relative to
the other metal complexes.
A

B

C

Figure 2.9. TEVC traces in Barth’s solution of (A) CuCl2, (B) 4, and (C) 3. Upward trend
represents channel block. The valley at time near 0 represents 0% block, 0 represents 100%
block, beginning of upward trend represents introduction of compound solution, red arrow
indicates when compound solution was replaced with compound-free rinse solution, and drop
after red arrow represents current recovery.
Comparison of the performance of CuCl2 and the copper complexes against S31N and H37A
shows that, in every case, their block against H37A had no slow phase increase and very closely
mirrored their fast-phase block against S31N. These observations strongly suggest that the
presence of any blocking compound was responsible for the fast-phase block and that the
presence of both histidine and copper was responsible for the slow-phase block and the much
lower current recovery relative to their respective ligands. Also noteworthy is the poor
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performance of 9 and 10, providing further evidence that the presence of the Amt or CO scaffold
is important to M2-S31N inhibition.
4. Conclusions
We confirmed that Cu2+ blocks the native M2 channel and also found that it blocks M2-S31N
in voltage-clamped transfected Xenopus oocytes. The washout shows that copper binds tightly in
both M2 constructs. When Cu2+ is complexed via IDA or IDAA with or without derivatives of
known M2 blockers, Amt or cyclooctylamine, the complexes block M2 channels comparably to
aquated Cu2+. When the Cu2+ is removed from the complex, the tight block is eliminated, which
suggests Cu2+ in the complex is adhering to the M2 channels. When the histidines are mutated to
alanines (H37A), the slow block is also eliminated, indicating that the copper complexes bind to
the histidines of the M2 channels during the slow phase. The copper complexes significantly
reduce, with low cytotoxicity, infection of MDCK cells with three IAV strains, two Amtinsensitive and one Amt-sensitive, and have EC50s in MDCK cell culture for the three strains of
IAV of 0.7–11.6 μM. Complexation reduces the cytotoxicity of Cu2+ approximately 10-fold.
Although the adamantyl and cyclooctyl moieties don’t affect the antiviral efficacy on the
long time scale, it is clear that they enhance M2 blocking on the short time scale of oocyte
experiments (2, 4 > 9 and 6, 8 > 10). One complex in particular, 4, is potent at sub-micromolar
concentrations against A/Calif/07/2009 H1N1, has a low cytotoxicity (average therapeutic index
67.8), and withstands decomposition in phosphate, sulfate, and nitrate containing buffers on the
timescale of infection and experiments. Considering the human dietary tolerance for copper and
the measured EC50s, we estimate that these complexes could be useful as novel treatments
against multiple strains of IAV. They could be delivered either by inhalant, orally in acid-
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resistant encapsulation, or intravenously. Resistance testing and animal testing are needed to
further explore these possibilities.
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CHAPTER 3

:

Crystal Structures and Influenza A Inhibition of
Divalent Polyamine Copper Complexes
Abstract
Influenza A (IVA) continues to pose a growing global threat even as current medications are
becoming less effective. One of the main avenues of research into new anti-IVA drugs is its M2
proton channel, especially the mutant M2-S31N (M2A). Building on the foundation of past
copper-containing M2A blockers targeting the M2A-H37 cluster, a series of copper complexes
featuring polyaza or polyamine chelators was developed. The effects of complex charge and
stability on ability to block M2A are examined. Complex 3, and its ligand 3L, were novelly
synthesized and all complexes were fully characterized. The crystal structure of 3, as well as that
of 1 and 2, were solved and are reported. The inverted-twin structure of 1, the tight packing and
high stability of 2, and the alternating hydrophobic and hydrophilic bands of 3 are discussed.
Though these complexes showed M2A inhibition inferior to previous anti-M2A copper
complexes, these complexes are useful to guide the direction of metal-containing M2A blockers.
1. Introduction
The influenza A virus (IVA) continues to be a global problem, especially for the very young
and the elderly.1 Amantadine (Amt), or adamantylamine, was an effective anti-IVA drug that
targeted the virus’s Matrix 2 proton channel V27 and S31 sites, until it was made obsolete in the
early 2000s when the IVA Matrix 2-S31N mutation (M2A) became nearly ubiquitous across all
IVA strains.2 Amt worked by blocking the influx of protons through M2-WT to disable the virus,
employing both hydrogen bonding through its amine and hydrophobic interactions through the
hydrocarbon ring, thereby preventing the activation of the viral RNA transfer process.3 For the
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past two decades, research has been ongoing to discover replacement drugs to fight IVA, much
of which has centered around replacing Amt with effective small organic ligand M2A-S31N
inhibitors (see Chapter 1).
Our team has focused on developing metal chelates using N-substitution of amantadine or
similar cyclic amines, adding “arms” that could bind the metal center while leaving it free
enough to bind M2A at its absolutely conserved H37 site. Because copper has been shown to
dramatically outperform other first-row transition metals in M2A-H37 binding strength and
irreversibility, we chose copper as our metal of interest.4,5 Because of copper’s toxicity, however,
decomplexation and cytotoxicity were a primary concern in our research.6
Our previous work comprised the formation and in vitro testing of neutral trichelate copper
complexes as novel anti-IVA drug candidates (Gordon et al., 2017). That line of research found
that, while copper complexes of amantadine iminodiacetate (Amt-IDA), amantadine
iminodiacetamide (Amt-IDAA), cyclooctyl iminodiacetate (CO-IDA), and cyclooctyl
aminodiacetamide (CO-IDAA) (Figure 3.1) were effective at blocking the M2A-S31N channel at
low-micromolar concentrations, the Cu(Amt-IDAA) and Cu(CO-IDAA) complexes lacked the
high stability possessed by the Cu(Amt-IDA) and Cu(CO-IDA) complexes when dissolved in
water. Further, we found that the cyclooctyl scaffold was as effective as the Amt scaffold, though
its lack of a rigid structure made characterizing it somewhat more difficult, especially by single
crystal X-ray diffraction (SC-XRD).
In this work, we chose to develop polyamine complexes of Cu2+ charge that would be
dicationic in aqueous solution. The amines would also be stronger ligands than the previously
used carboxylic acids and increase the stability of the copper complexes. We chelated copper
with 1,4,7,10-tetraazacyclododecane (cyclen), 1,3,7-triazacyclononane (TACN), and N,N’-bis(2-

50
pyridylmethyl)amantadine (Figure 3.1). Using cyclen with various copper salts to determine a
good counter anion, we decided on sulfate, it being more biologically benign than perchlorate
and having superior lattice properties to chloride in the solid state.

Cu(Amt-IDA)

Cu(Amt-IDAA)

Cu(cyclen)Cl2

Cu(cyclen)(ClO4)2

Cu(CO-IDA)

Cu(CO-IDAA)

Cu(TACN)SO4

Cu(Ad-BPA)SO4

Cu(Ad-MeCy)SO4

Figure 3.1. Structures of neutral and divalent copper complexes. Structures detail (A) Previously
reported work with neutral complexes, and (B) This work with divalent complexes.
Cyclen has a long history as a polyaza macrocycle for metal complexation, and along with its
cousin, cyclam, acts as a powerful 1:1 metal chelator, particularly for copper.8 For instance, Kim
and coworkers showed that cyclen could be embedded in a larger macrocycle, and they further
demonstrated that copper and zinc behaved very similarly when complexed by cyclen in that
system.9 Additionally, our group showed that a zinc-cyclen-resorcinarene structure can act as an
effective stationary phase for anion separation,10 while the uncomplexed cyclen-resorcinarene
showed limited effect in the same application.11 Research is still ongoing in cyclen metal
complexes, as Tsebrikova and coworkers recently reported on the synthesis and characterization
of the first octacoordinate cyclen complexes incorporating divalent zinc and cobalt.12
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The rigid structure of metal-cyclen complexes makes them ideal for crystallography,
especially when coupled with a hydrogen bonding-active anion such as perchlorate or sulfate.
One point of interest in metal-cyclen crystal structures includes the complexes’ puckered
geometry, usually mentioned as the M-(plane N4) distance.12 The packing structure can also yield
important information; the rapid decay of some complexes can be attributed to their loose
packing and easy escape of solvent molecules.12 In the case of copper-cyclen complexes, JahnTeller distortion in the Cu(II) makes the distance of the axial bond interesting as well.13
A great number of crystal structures have been reported for metal-cyclen complexes. Indeed,
over 200 structures were found for copper-cyclen and zinc-cyclen complexes alone. Most of
these are for substituted cyclen rings, however. One study was found that reported structures for
two different hydration states of Cu(cyclen)SO4,13 and another for Cu(cyclen)(NO3)2.14 However,
no structures were found for the unsubstituted complexes of dichloro copper-cyclen (1) or
diperchlorato copper-cyclen (2). These structures will be reported here.
Additionally, while extensive work has been performed with substituted cyclens, and there
are many known structures with amantadine groups bound to transition metals, no crystal
structure was found in the Cambridge Crystallographic Data Centre (CCDC) database with an
adamantane substituent on a cyclen or cyclam ring. Some applications could benefit from the
conjunction of the site specificity and increased lipophilicity of adamantane with a strongly
bound transition metal, such as preferential targeting of M2A. Additionally, adamantane’s ability
to enhance other pharmacological properties, such as pharmacokinetics, stability and distribution
in blood plasma, channel blocking and fitting for other cavities, and transport through lipids,
could particularly aid research in these fields.15 For example, an adamantane-substituted metalcyclen complex could target drug delivery for protein inhibition as the adamantane could direct
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the complex to a particular binding site while the metal binds a nearby residue through its open
axial site.
In the work detailed herein, we explored binding copper to neutral polyamine chelates,
resulting in divalent complexes (Figure 3.1, B). Unlike our previous work, we synthesized
tetrachelate complexes in addition to trichelates and used nitrogens as the chelating atoms to
create stronger metal-ligand bonds in an attempt to increase stability. We explored the
heterocyclic chelators cyclen (1-3) and TACN (4) as well as an amantadyl derivative of
dipicolylamine (5). The novel ligand with cyclen bonded to adamantyl was synthesized and
bound to copper (3). We also solved crystal structures of 1-3, which are unknown in the literature
and will be discussed here. The M2A blocking results for the complexes will also be given.
2. Experimental
2.1. Synthesis
2.1.1. General considerations
All reagents were of analytical grade and were purchased commercially and used without
further purification. Cyclen (1L, 2L) was obtained commercially and used as received. 1H
and 13C-NMR spectra were recorded on a Bruker 500 MHz multinuclear FT-NMR spectrometer.
Proton chemical shifts were reported in parts per million (δ) with reference to tetramethylsilane
(TMS, δ 0.0 ppm) or their respective solvent peaks. Mass measurements were done on an
Agilent model G1969A LC/MSD TOF mass spectrometer.
CAUTION! While no problems were experienced with the salts in this study, perchlorate
salts of metal complexes and organic ligands are potentially explosive and should be handled
with care.
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2.1.2. Synthesis of Cu(Cyclen)Cl2 (1)
This procedure was modified from literature.16,17 Copper chloride dihydrate (0.68 g, 4.0
mmol) was dissolved in 15 mL of methanol. Separately, cyclen (0.69 g, 4.0 mmol) was dissolved
in 15 mL of methanol. The copper solution was added to the cyclen solution, and a color change
to dark blue occurred immediately. The mixture was refluxed for 30 minutes, and the volume of
the resulting solution was reduced by half. Diethyl ether was added, causing blue and green
crystals of 2 to precipitate. More diethyl ether was added, and blue crystals precipitated. The
crystals of 1 were collected in 89% yield (1.0886 g).
2.1.3. Synthesis of Cu(Cyclen)(ClO4)2 (2)
This complex was synthesized according to a procedure from the literature in 88.4% yield.16
2.1.4. Synthesis of N-((adamant-1-yl)methyl)-cyclen (3L)
The reaction was performed under dry conditions under a nitrogen atmosphere. Cyclen
(1.3782 g, 8.0 mmol) was dissolved in 60 mL acetonitrile in a pressure vessel, and triethylamine
(2.80 mL, 20.1 mmol) was added to this solution while stirring. Separately, 1-(bromomethyl)adamantane (0.9181 g, 4.0 mmol) was dissolved in 30 mL acetonitrile, and this solution was then
slowly added to the cyclen solution. The pressure vessel was sealed, and the reaction was
refluxed at 150 °C for 6 days. The resulting cloudy solution was filtered under ambient
atmosphere and rinsed with acetonitrile at 0 °C, and the resulting white residue was dried under
vacuum to give a 44% yield (0.5669 g) of product. 1H-NMR (500 MHz, CDCl3): δ (ppm) 2.84 (s,
2H, NH), 2.80 (s, 4H, cyclen CH2), 2.65 (s, 4H, cyclen CH2), 2.58 (s, 4H, cyclen CH2), 2.52 (s,
4H, cyclen CH2), 2.06 (s, 2H, bridging CH2), 1.97 (s, 3H, adamantane CH), 1.65 (m, 6H,
adamantane CH2), 1.56 (d, 6H, adamantane CH2), 1.06 (s, 1H, NH). 1H-NMR (500 MHz, CDCl3
+ 2 drops CH3OH): δ (ppm) 2.78 (s, 4H, cyclen CH2), 2.62 (s, 4H, cyclen CH2), 2.55 (bs, 8H,
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cyclen CH2), 2.08 (s, 2H, bridging CH2), 1.98 (s, 3H, adamantane CH), 1.68 (m, 6H, adamantane
CH2), 1.55 (d, 6H, adamantane CH2). HRMS (ESI) m/z: calculated for [C19H36N4 + H+]
321.3013; Found: 321.3012.
2.1.5. Synthesis of [Cu(N-((adamant-1-yl)methyl)-cyclen)]SO4 (3)
CuSO4∙5H2O (0.2500 g, 1.0 mmol) was dissolved in 50 mL of water and poured over solid
N-((adamant-1-yl)methyl)-cyclen (0.3201 g, 1.0 mmol), and the solution immediately turned
dark blue. The solution was refluxed for 48 hours, and the solvent was removed under vacuum.
The resulting blue solid was recrystallized via evaporation of methanol. This mixture was filtered
and the solid rinsed with acetone, which caused more solid to precipitate in the filtrate. The
filtrate was filtered again, and both solids were collected as an indigo powder in 44% yield
(0.2093 g). 1H-NMR (500 MHz, DMSO-d6): no compound peaks. 1H-NMR (500 MHz, DMSOd6 + 30 μL DCl [35% w/w in D2O]): δ (ppm) 3.44 (bs, 12H, cyclen non-α-CH2), 3.27 (bs, 4H,
cyclen α-CH2), 3.13 (bs, 2H, bridging CH2), 2.03 (bs, 3H, adamantane CH), 1.89 (bs, 6H,
adamantane CH2), 1.61 (bs, 6H, adamantane CH2). HRMS (ESI) m/z: calculated for
[Cu(C19H36N4) - H+] 382.2152, [Cu(C19H36N4) + CHO2-] 428.2207; found: 382.2151, 428.2210.
2.1.6. Synthesis of TACN (4L)
TACN was synthesized as previously described18 and refrigerated between uses in a sealed
flask evacuated with nitrogen.
2.1.7. Synthesis of [Cu(TACN)]SO4 (4)
This procedure was identical to the synthesis of 2 using TACN instead of cyclen and the
sulfate salt of copper instead of perchlorate.
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2.1.8. Synthesis of N,N’-bis(2-pyridylmethyl)amantadine (5L)
This compound was synthesized according to a procedure from the literature in 38.1%
yield.19
2.1.9. Synthesis of [Cu(N,N’-bis(2-pyridylmethyl)amantadine)]SO4 (5)
The synthesis of this complex was modified from a literature procedure for the acetate salt.19
5L (0.2512 g, 0.51 mmol) was dissolved in 25 mL of methanol, and, separately, CuSO4·5H2O
(0.3729 g, 1.50 mmol) was dissolved in 35 mL of methanol. The solution of 5L was slowly
added to the CuSO4·5H2O, resulting in a dark blue solution. The solution was stirred overnight,
and the methanol was allowed to evaporate. 5 was collected as dark blue crystals in 63.9% yield
(0.2372 g).
2.2. Refinement
A crystal was harvested under oil in ambient conditions and placed at the tip of a polyimide
loop. The crystal was mounted in a stream of cold N2 and centered in the X-ray beam using a
video camera. Low-temperature (100 K) X-ray diffraction data comprising φ- and ω-scans were
then collected using a MACH3 kappa goniometer coupled to a Bruker Apex II CCD detector
with a Bruker-Nonius FR591 rotating anode X-ray source producing Cu Kα radiation (λ =
1.54178 Å). The Bruker APEX3 suite was used to process the data; reflection intensities were
integrated through the program SAINT, and appropriate absorption corrections were applied to
the intensities via a multi-scan method using the program SADABS.
The structure was solved using dual-space methods in SHELXT20 and refined against F21 on
all data by full-matrix least squares with SHELXL-201421 using established refinement
strategies.22 All non-hydrogen atoms were refined anisotropically. The positions of all hydrogen
atoms bound to carbon were calculated geometrically and refined using a riding model. The
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positions of hydrogen atoms bound to the amine (N1-N8), alcohol (O1s), and fully occupied
water (O3 and O4) groups were taken from the difference Fourier synthesis and subsequently
refined semi-freely with the help of appropriate distance restraints. The isotropic displacement
parameters of all hydrogen atoms were constrained to be 1.2 times the Ueq value (1.5 for methyl
hydrogens) of the atom to which they are bound. For the final cycle of refinement, reflections
obstructed by the beamstop or clear outliers were omitted.
3. Results and Discussion
3.1. Synthesis of 3L and 3
To make the novel compound containing cyclen and adamantyl (3L), 1(bromomethyl)adamantane was added to cyclen, precipitated from the solution, and purified by
rinsing with acetonitrile. Because 3L was insoluble in polar solvents and copper sulfate was
insoluble in non-polar solvents, aqueous copper sulfate was combined with solid 3L. Complex
formed, remained in the aqueous phase, and was recrystallized from methanol.
Complexes 3 and 3L were characterized as discussed below. The characterization of all other
ligands and complexes matched the characterization provided in their respective literature
references. The characterizations of 1, 2, 4, 4L, 5, and 5L will not be discussed here.
1

H-NMR spectra were collected for 3L (Figure 3.2) and with deuterated methanol added to

determine the amine peak (Figure 3.3). Spectra were also collected for 3 without (Figure 3.4) and
with (Figure 3.5) deuterium chloride (DCl) added to remove the copper’s paramagnetic influence
on the ligand. Thus, the 3L spectrum should be equivalent to the spectrum for 3 plus DCl.
However, unlike 1 and 2, 3 was unchanged by trifluoroacetic acid, indicating that the Cu-N
bonds were much stronger in 3. Thus, the broad peaks seen in the spectrum of 3 plus DCl may
indicate that, even with the stronger acid, the copper was only partially removed from the ligand.

57

Figure 3.2: 1H-NMR (500 MHz) of 3L in CDCl3 before addition of methanol-d4. Peak
assignments (ppm): 7.27 (s, CHCl3), 2.84 (s, 2H, NH), 2.80 (s, 4H, cyclen CH2), 2.65 (s, 4H,
cyclen CH2), 2.58 (s, 4H, cyclen CH2), 2.52 (s, 4H, cyclen CH2), 2.06 (s, 2H, bridging CH2),
1.97 (s, 3H, adamantane CH), 1.65 (m, 6H, adamantane CH2), 1.56 (d, 6H, adamantane CH2),
1.06 (s, 1H, NH), 0.00 (s, TMS).

Figure 3.3: 1H-NMR (500 MHz) of 3L in CDCl3 after addition of 2 drops of methanol-d4. Peak
assignments (ppm): 7.42 (s, CHCl3), 3.36 (CH3OH), 2.78 (s, 4H, cyclen CH2), 2.62 (s, 4H,
cyclen CH2), 2.55 (bs, 8H, cyclen CH2), 2.08 (s, 2H, bridging CH2), 1.98 (s, 3H, adamantane
CH), 1.68 (m, 6H, adamantane CH2), 1.55 (d, 6H, adamantane CH2), 0.00 (s, TMS).
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Figure 3.4: 1H-NMR (500 MHz) of 3 in DMSO-d6 before adding deuterium chloride. Peak
assignments (ppm): 3.37 (s, H2O), 2.50 (s, DMSO).

Figure 3.5: 1H-NMR (500 MHz) of 3 in DMSO-d6 after addition of deuterium chloride. Peak
assignments (ppm): 5.12 (bs, H2O), 3.44 (bs, 12H, cyclen non-α-CH2), 3.27 (bs, 4H, cyclen αCH2), 3.13 (bs, 2H, bridging CH2), 2.50 (s, DMSO), 2.03 (bs, 3H, adamantane CH), 1.89 (bs,
4H, adamantane CH2 spatially closer to Cu), 1.61 (bs, 8H, adamantane CH2).
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This made integration somewhat unreliable, and it also resulted in unique splitting of the
adamantyl CH2 peaks, with those closer in proximity to the copper ion being split from the others
(Fig. 3.10 for spatial referencing).
Mass spectra were obtained on a high-resolution mass spectrometer (HRMS) for 3 and 3L.
The spectrum for 3L contained a standard M+H+ peak (321.3012 m/z) and was otherwise clean
(Figure 3.6). The spectrum for 3 contained peaks for M-H+ (382.2151 m/z) and M+CHO2(428.2210 m/z), with formate coming from the MS buffer (Figure 3.7). The MS instrument is set
to detect plus one species and thus the M+2 species is not observed. The M+2 isotope peak shows
the complex contains one Cu.

Figure 3.6. Mass spectrum of 3L. The compound was found as an M+H peak at 321.3012 m/z.

Figure 3.7. Mass spectrum of 3. The complex was found as an M-H peak at 382.2151 and an
M+CHO2- peak at 428.2210.
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3.2. Crystal structures
Crystals of 1 (from blue solid of second crop) and 2 were grown from a concentrated solution
in methanol, to which was slowly added diethyl ether in a 2:1 ratio of ether to methanol to form
two layers, which were allowed to mix slowly. The first crystals of 1 were discarded for lack of
clarity, and single crystals were grown from the mother liquor by slow evaporation followed by
further addition of diethyl ether. Crystals of 3 were grown from methanol in the presence of
acetone vapors in a sealed container. All crystals were left in their respective mother liquors until
harvesting immediately before measurement by SC-XRD. Table 3.1 shows crystallographic data
collected and parameters used. Included is data about the crystal itself, parameters of the data
collection, and parameters for the pattern refinement.
Several anions were considered to counterbalance the copper charge for crystallization, as
seen in complexes 1-3. Both chloride (1) and perchlorate (2) were chosen for test syntheses
because they were easy to use for synthesis, though recrystallizing 2 was markedly easier than
recrystallizing 1. This was thought to be due to the perchlorate, as a larger anion, being able to
pack better, creating a tighter, more stable lattice with little room for disorder. Some
intermolecular hydrogen bonds were also observed in 2, but as perchlorate is a relatively weak
hydrogen-bond acceptor, this probably had only a small effect on the overall formation and
stability of the crystal. While hydrogen bonding existed in 1, it was only from the free chloride,
and that at only one point on each molecule, leaving most of the looser solid lattice more capable
of disorder (Figure 3.8). While 2 seemed like the better choice, the dangers of perchlorate salts,
both as physiological oxidizers and as dry solids, made it unusable as a potential drug candidate.
Sulfate was chosen as a physiologically benign anion capable of multiple binding methods, such
as stronger hydrogen bonds than those of perchlorate. The sulfate equivalent of 1 and 2 (not
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shown) was synthesized as a proof of concept before copper sulfate was used in the synthesis of
3-5.
Table 3.1. Crystallography data for 1, 2, and 3. Data were collected on a Bruker Apex II CCD at
100K with Cu Kα radiation. Absorption correction performed semi-empirically from equivalents.
Property

1

2

3

Cu(C8H20N4)(ClO4)2

Cu(C8H20N4)Cl2

Cu(C19H36N4)(H2O)(SO4)(C2H6O)0.5

434.72

306.72

498.14

Monoclinic, P21/n

Tetragonal, P4212

Triclinic, P-1

a, b, c (Å)

8.8994 (4), 15.0259 (6),
11.8776(5)

9.3424 (10), 9.3424
(10), 7.3854 (8)

7.3851 (5), 16.6885 (12),

α, β, γ (°)

90, 92.797 (2), 90

90, 90, 90

79.850 (3), 83.065 (3), 81.780 (3)

1586.40 (12)

644.60 (15)

2416.1 (3)

4

2

2

5.498

6.011

2.487

0.15 x 0.13 x 0.04

0.44 x 0.30 x 0.14

0.33 x 0.25 x 0.18

Tmin, Tmax

0.464, 0.585

0.134, 0.273

0.556, 0.661

No. of measured,
independent and observed
[I > 2σ(I)] reflections

19935, 2898

8661, 597

53713, 8764

0.0506

0.0451

0.0493

0.0232, 0.0574, 1.110

0.0320, 0.0849, 1.030

Crystal data
Chemical formula
Mr
Crystal system, space
group

V (Å3)
Z
μ (mm−1)
Crystal size (mm)

20.2197 (15)

Data collection

Rint
Refinement

R[F2 > 2σ(F2)], wR(F2), S 0.0275, 0.0754, 1.076
No. of reflections

19935

8661

8764

No. of parameters

220

125

677

4

54

1366

0.54, -0.35

0.34, -0.59

0.50, -0.46

No. of restraints
Δρmax, Δρmin (e Å−3)
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Figure 3.8. Hydrogen bonding in the crystal lattice of 1. Gray spheres are carbon, dark blue are
nitrogen, cyan are copper, and green are chlorine. Hydrogens have been left off, but reside on the
nitrogens.
The three copper-cyclen complexes for which crystal structures were determined (1-3) were
compared to a crystal structure of [CuH2O(cyclen)]SO4∙2-3H2O (6) from the literature.13 All of
the structures were similar in that they crystallized in a distorted square-pyramidal geometry with
the metal center “puckered” above the plane of the four nitrogens (planeN, Figure 3.9). Our group
has seen a similar trait of copper to assume a distorted geometry between square pyramidal and
trigonal bipyramidal in Cu(Amt-IDA) from our previous work. This tendency was attributed to
Jahn-Teller distortion producing a decreased energy state with two of the metal-ligand bonds
axial rather than only one,7 which was supported by the “puckering”effect decreasing in the
order 1 > 3 > 6 > 2 as the structure was stabilized by increasing rigidity in the crystal lattice due
to hydrogen bonding (Table 3.2).
Interestingly, 1 crystallized in an inverted-twin fashion, making it unique among the found
Cu(cyclen) crystal structures. The twin structures were subjected to Mercury’s automatic overlay
feature allowing free rotation, but the best overlay (not shown) looked much like the actual
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A

B

C

Figure 3.9. Crystal structures of (A) 1, (B) 2, and (C) 3. Gray spheres are carbon, dark blue are
nitrogen, cyan are copper, green are chlorine, red are oxygen, and yellow are sulfur.
Table 3.2. Selected bond lengths and distances (Å). Calculated values listed represent the
average of multiple close values. Real values less than ±0.005 Å from the average were used
where available with their uncertainty included.
Length

1a

2

3b

6c

Cu-planeN dist.c,d

0.630

0.480

0.546

0.530

Cu-N length

1.995(8), 2.081(6)

2.0108(17)

2.0921(15),
2.0203(16)

2.116

Bisecting N-N dist.c

3.967

3.894

3.972, 3.885

3.902

N-C length

1.479(10), 1.473(12)

1.483(3)

1.493, 1.482(2)

1.482

C-C length

1.52(2), 1.49(3)

1.517(3)

1.518(3), 1.508(3)

1.517

Separated values represent the two conformers 1A and 1B, respectively. bSeparated values represent the substituted
nitrogen and unsubstituted nitrogens, respectively, or, for the C-C length, carbons adjacent to the same. cValues
measured in Mercury software. dThe distance between the copper ion and the plane formed by the four nitrogens.

a
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crystal structure (Figure 3.10). However, when inversion was allowed, the structures
superimposed almost perfectly, though the small differences can be attributed to known
refinement difficulties of inversion twins. Indeed, the two disordered parts of the cyclen moiety
had opposite hands; the nitrogen atoms in the major component (N1A, 53% occupancy)
exhibited S chirality, and the nitrogen atoms in the minor component (N1B, 47% occupancy)
exhibited R chirality, though they were nearly equally represented. This disorder combined with
the somewhat ambiguous absolute structure of inversion twins indicated that both hands were
equally likely. In addition to coordinating with the copper center, the disordered amine groups
may have had some hydrogen bond-like interaction with the free-standing chloride counterion.
Each noncoordinating chloride ion has such interactions with four copper complexes, that the
chloride has roughly tetrahedral geometry. This results in a quilt-like packing of the complexes
in layers parallel to the ab plane with the thickness of each layer being the width of the c-axis.

Figure 3.10. Crystal structures of two conformers of 1. The copper and two chlorides were
aligned as static reference points. 1A is shown with black lines and 1B is shown with white lines,
with individual atoms labeled as A or B, respectively. Gray spheres are carbon, dark blue are
nitrogen, cyan is copper, and green are chlorine.
The closest analogue of 3 was 6, with which it had both several commonalities and several
differences. In both, the copper bonded with a solvent molecule, allowing the free sulfate, along
with other solvents of crystallization, to form a strongly interlaced hydrogen-bonding lattice.
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This can be seen on the hydrophilic end of 3 (Figure 3.11). Both were different than 1 and 2 in
that the copper center was bound to a solvent molecule instead of a counterion, and both 3 (0.546
Å) and 6 (0.530 Å) had roughly the same Cu-planeN distance relative to the distances seen in 1A
(0.630 Å) and 2 (0.480 Å). The N-C length of 6 (1.482 Å) matched the N-C length on the
unsubstituted nitrogen of 3 (1.482 Å) and was close to that for 1A and 2 (1.479 Å and 1.483 Å,
respectively) while the C-C length of 6 (1.517 Å) closely matched the C-C length of 3 (1.518 Å)
for the carbons adjacent to the substituted nitrogen and that of 2 (1.517 Å).

Figure 3.11. Hydrogen bonding in the crystal lattice of 3. Two unit cells are shown. Cyan lines
are hydrogen bonds within the unit cells shown, and red lines are hydrogen bonds extending to
other unit cells. Gray spheres are carbon, dark blue are nitrogen, orange are copper, yellow are
sulfur, and red are oxygen.
Of interest for 3 is that the N-Cu-N distance extending straight across from the substituted
nitrogen is the longest of all the N-Cu-N distances (3.972 Å), while the N-Cu-N distance
extending between the non-substituted nitrogens is the shortest of all of them (3.885 Å). These
values are slightly different from 1, the least rigid structure, for the longest (3.967 Å) and 2, the
most rigid structure, for shortest (3.894 Å). This suggests that the amantadine, which can freely
rotate at two points and relies on hydrophobic interactions for packing, decreases the rigidity of
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the structure along the connecting axis, while the other axis maintained stability with increased
rigidity along the axis that promoted the far better hydrogen-bonding lattice (Figure 3.12).
The packing arrangement of 3 lies with the hydrophobic adamantane cages facing toward
each other. The hydrophilic rings, counterions, and solvent molecules face toward each other in
an ABAB pattern of complexes extending along the b-axis. Together, the alternating hydrophilic
and hydrophobic b-axis “threads” form sheets along the ab plane.
The short, stable N-Cu-N axis of 3 followed the hydrophilic threads of the sheet, which
contain numerous hydrogen-bonding opportunities, while the hydrophobic amantadyl threads
were left to rely mostly on hydrophobic interactions for stability. Uniquely, though, the unit cell
of 3 contained two full

Figure 3.12. Crystal packing structure of 3. Gray spheres are carbon, dark blue are nitrogen,
cyan are copper, yellow are sulfur, and red are oxygen.
molecules placed side by side yet slightly askew from each other, and each of the two molecules’
counterions crystallized in a different orientation, presumably to allow for a more stable crystal
lattice. Contrarily, in the packing arrangement of 2, in which every molecule was identical, two
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molecules of compound lay tightly packed with their bound perchlorate counterions pointing
inward toward the ring of the other molecule in a shoe-like orientation, and the ring pointed out.
These units then packed sideways on top of each other, forming dense, independent columns
extending along the c-axis. In contrast to the packing structure for 3 and 1 (Figure 3.13), in
which the cyclen rings are parallel with the ab plane, the packing structure of 2 formed with the
cyclen rings lying parallel to the bc plane (Figure 3.14).
3.3 Viral studies
Aqueous solutions of complexes 1-5 were introduced to M2A, and in vitro TEVC assays and
efficacy studies were performed for the complexes as explained in our previous work.7 The
previous complexes exhibited superior performance to all complexes in this study in the
inhibition of M2A and IVA-M2A. This could have been due to size constraints of the complexes
in this study, as the complexes were significantly larger than our previous work. Due to the
copper’s ability to only bind through an axial site in the cyclic complexes, the Cu-His binding
may not have been strong enough to overcome displacement by ambient hydroniums at acidic
pH levels. The possible exception to this was 5, in which the fourth equatorial site was freer than
the cyclic complexes, though the steric crowding from the bis-pyridyl rings still made that
equatorial site less available to the imidazole nitrogen than Cu(Amt-IDA),19,7 especially if the
sterics were exacerbated by any repulsion between the aromatic π-electron clouds. Additionally,
because M2A is gated with a nonpolar V27 cluster, it may have rejected the highly polar divalent
complexes simply due to electrostatic incompatibility. Positive ions inside M2A, which is known
to house hydronium and sodium ions, may have prevented the complexes from entering to a
useful degree due to electromagnetic repulsion. Finally, because at least three of the H37
histidines are protonated when the channel is active, the repulsive positive charge of the H37

68

Figure 3.13. Crystal packing structure of 1. Gray spheres are carbon, dark blue are nitrogen,
cyan are copper, and green are chlorine.

Figure 3.14. Crystal packing structure of 2. Gray spheres are carbon, dark blue are nitrogen,
cyan are copper, green are chlorine, and red are oxygen.
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cluster—believed to be strong enough to drive the conformation change of the channel—may
have repelled the unmitigated, divalent charge of the copper ion, preventing it from binding to
the histidines.
4. Conclusions
A series of divalently charged copper complexes were synthesized containing three or four
aza or amino nitrogens. The ligand of one of these, 3L, was new, as was its sulfated copper
complex, 3, and the crystal structure thereof. Procedures for the novel syntheses of 3L and 3
were created, and the crystal structure of 3 was solved. In addition, the crystal structures of 1 and
2 were unknown to the CCDC database, so those structures were also solved from single
crystals. Of interest for 1 was the inverted twin crystallization structure, each of which displayed
opposite chirality in equal proportion. In 2, the much tighter packing structure formed
independent columns consisting of stacked, interposed pairs of molecules, though the
independent columns were packed loosely from one another. 3 displayed an interesting
arrangement of sheets formed with alternating “threads,” one with hydrophobic adamantanes
pointing toward each other and the other with the hydrophilic rings and ions pointing toward
each other. This left the cyclen axis with the adamantyl substitution relatively weak with longer
bonds and N-Cu-N distances than those of the other axis, which lay along the hydrophobic
threads and was made stronger by interlaced hydrogen bonding.
Complexes 1-5 were tested against M2A-S31N, and they exhibited neither significant
channel inhibition nor efficacy in saving infected MDCK cells compared to previous work. This
could be explainable by the size, electrostatic makeup, and/or binding options of the complexes
preventing them from binding the M2A-H37 residues at acidic pH. However, though divalentlycharged complexes were shown relatively ineffective, monovalently-charged complexes may

70
fare better, as the channel is designed to accommodate singly-charged ions. These complexes
could be a hybrid of our work performed here and that performed previously, binding the copper
ion with one anionic arm and one neutral arm joined by an Amt or CO scaffold.
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